naltrexone and Drug Withdrawal Symptoms

naltrexone has been researched along with Drug Withdrawal Symptoms in 462 studies

Research

Studies (462)

Timeframe	Studies, this research(%)	All Research%
pre-1990	85 (18.40)	18.7374
1990's	99 (21.43)	18.2507
2000's	158 (34.20)	29.6817
2010's	102 (22.08)	24.3611
2020's	18 (3.90)	2.80

Authors

Authors	Studies
Bousquet, AR; Howes, JF; Kotick, MP; Polazzi, JO	1
Fox, LM; Lee, JD; Nelson, LS; Smith, SW; Wightman, RS	1
Brewer, C	4
Akerman, SC; Barbieri, V; Bisaga, A; Fratantonio, J; Hu, MC; Nunes, EV; Shulman, M; Sullivan, MA	1
Schmitz, ZP; Soghoian, SE; Warstadt, NM	1
Angermaier, G; Carswell, N; Castaneda, C; Delgado, F	1
Candy, B; Jones, L; Larkin, PJ; Stone, P; Vickerstaff, V	1
Fogelman, N; Hermes, G; Hyman, SM; Kosten, TR; Sinha, R	1
Ashizawa, K; Hara, T; Ikeda, T; Ishii, K; Kamada, M; Komatsu, Y; Matsuo, K; Morishita, S; Ryu, E; Yamaguchi, M; Yamashita, H	1
Brown, JN; Elias, AM; Pepin, MJ	1
Bergman, J; Doyle, RJ; Kangas, BD; Porter, EN; Withey, SL	1
Bisaga, A; Levin, FR; Mariani, JJ; Mishlen, K; Nunes, EV; Sibai, M	1
Banks, ML; Negus, SS; Townsend, EA	1
Kunzler, NM; Nelson, LS; Wightman, RS	1
Kebir, O; Laqueille, X; Mouaffak, F	1
Babakhanlou-Chase, H; Bernson, D; Land, T; Larochelle, MR; Li, Y; Lodi, S; Walley, AY	1
Akerman, SC; Alam, D; Comer, SD; Douaihy, A; Mannelli, P; Nangia, N; Silverman, BL; Sullivan, MA; Zavod, A	1
Oberdick, J; Sadee, W; Wang, Z	1
Spitzberg, AJ; Urner, EM; Wirshing, WC	1
Calleo, VJ; Sullivan, RW; Szczesniak, LM	1
Basaraba, C; Bisaga, A; Brooks, DJ; Choi, CJ; Levin, FR; Mahony, AL; Mariani, JJ; Naqvi, N; Pavlicova, M	1
Greenland, M; Kelty, E; Preen, D; Terplan, M	1
al'Absi, M; Allen, S; Anker, JJ; Nakajima, M; Raatz, S	1
Gibaja, V; Gillet, P; Labroca, P; Lemarié, J; Martini, H; Paille, F; Petitpain, N; Yéléhé-Okouma, M	1
Franchitto, N; Jullian, B; Pelissier, F; Rolland, B; Salles, J	1
Woody, GE	1
Boney, TY; Chen, DT; Fishman, MJ; Friedmann, PD; Gordon, M; Hu, MC; Lee, JD; Nunes, EV; O'Brien, CP; Wilson, D	1
Ali, R; Gowing, L; White, JM	3
Bigelow, GE; Dunn, KE; Strain, EC; Tompkins, DA	1
Alto, W; Gianutsos, P; Mancl, L; Plawman, A; Rudolf, G; Rudolf, V; Walsh, J	1
Carton, L; Gaboriau, L; Lescut, C; Rolland, B	1
Astrup, A; Christensen, R; Johansen, KGV; Lund, H; Pagsberg, AK; Tarp, S	1
da Luz, SC; Nogueira, CW; Pesarico, AP; Rosa, SG; Tagliapietra, CF	1
Akerman, SC; Bisaga, A; Graham, CE; Kosten, TR; Mannelli, P; Nangia, N; Silverman, BL; Sullivan, MA; Tompkins, DA; Yu, M	1
Bommagani, SB; Crooks, PA; Dobretsov, M; Fantegrossi, WE; Gannon, BM; Mahelona, RD; Penthala, NR; Wan, A; Yadlapalli, JSK	1
Childress, AR; Fairchild, VP; Jagannathan, K; Langleben, DD; O'Brien, CP; Shi, Z; Wang, AL	1
Dziedowiec, E; Gruver, KS; Jennings, T; Nayak, SU; Rawls, SM; Tallarida, CS	1
Mannelli, P; Swartz, M; Wu, LT	1
Erikson, CM; Walker, BM; Wei, G	1
Broglio, K; Matzo, M	1
Pixton, GC; Setnik, B; Sommerville, KW; Webster, L	1
Martin-Fardon, R; Matzeu, A; Terenius, L	1
Barnett, BS; Suzuki, J; Ward, HB	1
Banks, ML; Blake, S; Bremer, PT; Faunce, KE; Hwang, CS; Janda, KD; Natori, Y; Townsend, EA; Zhou, B	1
Armstrong, SR; Beattie, DT; Campbell, CB; Hegde, SS; Long, DD; Richardson, CL; Tsuruda, PR; Vickery, RG	1
Gorelick, DA; Mannelli, P; Peindl, KS; Wu, LT	1
Afzali, S; Hassanian-Moghaddam, H; Pooya, A	1
Douaihy, AB; Kelly, TM; Sullivan, C	1
Gillett, K; Harshberger, E; Valdez, GR	1
Brewer, C; de Jong, C; Williams, J	1
Corder, G; Donahue, RR; Doolen, S; He, Y; Hu, X; Jutras, BL; McCarson, KE; Mogil, JS; Storm, DR; Taylor, BK; Wang, ZJ; Wieskopf, JS; Winter, MK	1
Crawford, EF; George, O; Koob, GF; Park, PE; Schlosburg, JE; Vendruscolo, LF; Whitfield, TW	1
Heinz, A; Müller, CA	1
Hashemian, M; Kolahi, AA; Mohajerani, SA; Mottaghi, K; Safari, F; Salimi, A	1
Mannelli, P; Peindl, KS; Swartz, MS; Woody, GE; Wu, LT	1
Garg, A; Kumar, P; Prakash, O; Sinha, P	1
Ciccocioppo, R; Economidou, D; Heilig, M; Kinoshita, H; Kuriyama, M; Roberto, M; Stopponi, S; Teshima, K; Weiss, F	1
Gao, MJ; Kao, JH; Law, PY; Loh, HH; Tao, PL; Yang, PP	1
Besirli, A; Eşel, E; Özsoy, S; Turan, T	1
Schairer, J; Thapa, SD	1
Kelsey, JE; Schierberl, KC; Verhaak, AM	1
Adamson, SJ; Berks, J; Cape, G; Deering, D; Dunn, A; Foulds, JA; Frampton, CM; Nixon, L; Sellman, JD	1
Gibula-Bruzda, E; Izdebski, J; Kotlinska, JH; Marszalek-Grabska, M; Witkowska, E	1
Dakwar, E; Kleber, HD	1
Hang, A; Liu, JG; Liu, Y; Shu, XH; Wang, Q; Wang, YJ; Zan, GY	1
Donnerstag, N; Lüthi, A; Mehlig, A; Raetz Bravo, A; Schneider, T; Taegtmeyer, A	1
Kissler, JL; Walker, BM	1
Bisaga, A; Carpenter, KM; Glass, A; Haney, M; Levin, FR; Mariani, JJ; Mishlen, K; Nunes, EV; Pavlicova, M; Raby, WN; Sullivan, MA	1
Froehlich, JC; Kincaid, CL; Rasmussen, DD	1
Batisse, A; Boucher, A; Chavant, F; Daveluy, A; Diot, C; Donadieu-Rigole, H; Eiden, C; Peyrière, H; Roussin, A	1
Gofman, AG; Ponizovskiy, PA	1
Higuchi, S; Yumoto, Y	1
Dahmke, H; Kullak-Ublick, GA; Kupferschmidt, H; Weiler, S	1
Daniels, S; Leri, F; Marshall, P	1
Franchitto, N; Nubukpo, P; Pélissier, F; Rougé Bugat, ME	1
Jiang, GH; Lv, XF; Ma, XF; Qiu, YW; Su, HH; Tian, JZ; Zhuo, FZ	1
Sushchyk, S; Wang, JB; Xi, ZX	1
Ling, Y; Oberdick, J; Phelps, MA; Sadee, W; Schilling, K; Yudovich, MS	1
Anderson, B; Bailey, G; Herman, D; Stein, M; Uebelacker, LA	1
Allen, S; Grabowski, J; Hatsukami, DK; Mooney, ME; Oliver, A; Pentel, P; Schmitz, JM	1
Klein, JW	1
Alongkronrusmee, D; Chiang, T; van Rijn, RM	1
Di Giannantonio, M; Di Nicola, M; Janiri, L; Martinotti, G	1
Cooney, JL; Cooney, NL; McKee, SA; O'Malley, SS; Toll, BA	1
Carroll, FI; France, CP; Li, JX; McMahon, LR	1
Soyka, M	1
Gorelick, DA; Gottheil, E; Mannelli, P; Patkar, AA; Peindl, K; Wu, LT	1
Becker, GL; France, CP; Gerak, LR; Koek, W	1
Baraban, JM; Crombag, HS; Dinenna, ML; Guo, N; Holland, PC; Huganir, RL; Reti, IM; Sutton, JM; Takamiya, K	1
Beck, O; Franck, J; Hammarberg, A; Jayaram-Lindström, N	1
Fishman, M	1
Lloyd-Jones, DM	1
Little, M; Murray, LM	1
Brewer, CL	1
Kozminsky, MP	1
Kalivas, PW; Lai, M; Liu, H; Tang, S; Zhang, F; Zhou, W; Zhu, H	1
Scavone, JL; Van Bockstaele, EJ	1
Sharma, B; Singh, SM	1
Andreoli, S; Bria, P; De Filippis, R; Di Giannantonio, M; Di Nicola, M; Janiri, L; Martinotti, G; Mazza, M; Moroni, N; Pomponi, M; Pozzi, G; Reina, D; Romanelli, R; Tedeschi, D	1
Cummins, ET; Younger, JW; Zautra, AJ	1
Avila, MA; Brandão, ML; Castilho, VM; De Ross, J; Nobre, MJ; Ruggiero, RN	1
Acquas, E; Ibba, F; Kasture, S; Lecca, D; Marongiu, M; Murali, B; Pisanu, A; Puddu, A; Vinci, S; Zernig, G	1
Bing, G; Jang, CG; Kim, HC; Koo, KH; Nabeshima, T; Oh, CH; Oh, KW; Park, DH; Shin, EJ; Yamada, K	1
Barr, GA; McPhie, AA	2
Choi, SM; Jung, JS; Kwon, MS; Lee, JK; Park, SH; Seo, YJ; Sim, YB; Suh, HW	1
Burnand, B; Nanchen, D; Peytremann-Bridevaux, I; Walther, MR; Willi, C	1
Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS	1
Frey, R; Gleiss, A; Kasper, S; Naderi, A; Naderi, MM; Naderi-Heiden, A; Rahmani-Didar, F; Salimi, AR	1
Bilsky, EJ; Giuvelis, D; Lowery, JJ; Osborn, MD; Skorput, AG	1
Bramness, J; Gossop, M; Lobmaier, P; Waal, H	1
Hoffman, RS; Jang, DH; Nelson, LS; Rohe, JC	1
Björkholm, C; Franck, J; Häggkvist, J; Lindholm, S; Schilström, B; Steensland, P	1
Lemesle, F; Nicola, W; Pierre Jonville-Béra, A	1
Koob, GF; Walker, BM; Zorrilla, EP	1
Brissett, DI; van Rijn, RM; Whistler, JL	1
Gossop, M; Hegstad, S; Hjerkinn, B; Kristensen, Ø; Kunøe, N; Lobmaier, P; Vederhus, JK; Waal, H	1
Malek, S; Mottaghi, K; Safari, F; Salimi, A	1
Amar, R; Casarella, J; Drexler, K; Fareed, A; Vayalapalli, S	1
Bergman, J; Paronis, CA	1
Anton, RF; Baros, AM; Latham, PK; Myrick, H; Randall, PK; Waid, LR; Wright, TM	1
Gorelick, DA; Mannelli, P; Patkar, AA; Peindl, K; Tharwani, HM; Wu, LT	1
Cooney, GA; Israel, RJ; Karver, S; Lipman, AG; Stambler, N	1
Finigan, MW; Parks, J; Perkins, T; Stringer, M; Zold-Kilbourn, P	1
Bisaga, A; Carpenter, KM; Cheng, WY; Levin, FR; Mariani, JJ; Nunes, EV; Raby, WN; Sullivan, MA	1
Bihel, F; Bockel, F; Bourguignon, JJ; Elhabazi, K; Maldonado, R; Meziane, H; Mollereau, C; Moulédous, L; Petit-demoulière, B; Schmitt, M; Simonin, F; Trigo, JM; Zajac, JM	1
Carlezon, WA; Chartoff, E; Pliakas, A; Potter, D; Rachlin, A; Sawyer, A	1
Madia, PA; Navani, DM; Sirohi, S; Yoburn, BC	1
Gorelick, DA; Mannelli, P; Patkar, AA; Peindl, K; Wu, LT	1
Bhatia, KS; Lee, T; Mannelli, P; Peindl, KS; Wu, LT	1
Bisaga, A; Kosten, T; Nunes, EV; O'Connor, PG; Sigmon, SC; Woody, G	1
Harshberger, E; Valdez, GR	1
Natividad, LA; O'Dell, LE; Orfila, JE; Tejeda, HA; Torres, OV	1
Clark, DB	1
Dewey, WL; Gerk, PM; He, H; Kozak, P; Li, G; Mitra, P; Scoggins, KL; Selley, DE; Stevens, DL; Yuan, Y; Zhang, Y	1
Carlsson, A; Feltmann, K; Franck, J; Fredriksson, I; Holst, S; Schilström, B; Steensland, P	1
Bart, G	1
Koob, GF; Misra, KK; Schlosburg, JE; Vendruscolo, LF; Wee, S	1
Law, F; Melichar, J; O'Shea, J; Praveen, KT	1
Banks, ML; Negus, SS	1
Chavkin, C; Chavkin, NW; Gustin, RM; Hagan, CE; Lemos, JC; Messinger, DI; Neumaier, JF; Schattauer, SS; Schindler, AG; Shankar, H; Smith, JS	1
Frost, JJ; Kuwabara, H; McCaul, ME; Wand, GS; Weerts, EM; Wong, DF; Xu, X	1
Clark, N; Verster, A	1
Ali, R; Gowing, L; McGregor, C; Thomas, P; White, JM	1
Ho, IK; Rockhold, RW; Sinchaisuk, S	1
Holtzman, SG; Kalinichev, M	1
Holtzman, SG	3
Bertschy, G; Besson, J; Bochud Tornay, C; Daeppen, JB; Favrat, B; Monnat, M; Schnyder, C	1
Holtzman, SG; White, DA	1
Aghajanian, GK; Gold, SJ; Han, MH; Herman, AE; Liu, RJ; Mumby, SM; Nestler, EJ; Ni, YG; Potts, BW; Pudiak, CM	1
Ciccocioppo, R; Lin, D; Martin-Fardon, R; Weiss, F	1
Chiao, F; Erice, S; Leverone, T; Ma, H; Pearce, S; Quon, R; Tang, J; Wender, RH; White, PF	1
Fan, LW; Ho, IK; Ma, T; Park, Y; Rockhold, RW; Sasaki, K; Tanaka, S; Tien, LT	1
Baraban, JM; Reti, IM	1
Besson, JM; Gestreau, C; Le Guen, S	1
Heinz, A; Mann, K; Wilwer, M	1
Armstrong, PA; Boyce, SH; Stevenson, J	1
Armstrong, J; Little, M; Murray, L	1
Bussandri, M; Ceresini, S; Esposito, A; Gerra, G; Moi, G; Molina, E; Raggi, MA; Zaimovic, A	1
Raffa, RB; Stagliano, GW; Umeda, S	1
France, CP; McMahon, LR; Sell, SL	1
Grinenko, AIa; Krupitskiĭ, EM; Zvartau, EE	1
Bilsky, EJ; Kieffer, BL; Lin, ET; Lowery, JJ; Raehal, KM; Sadée, W; Wang, D	1
Ali, R; Athanasos, P; Danz, C; Gowing, L; McGregor, C; Stegink, A; Thomas, P; White, J	1
Koutsogiannis, Z; Kronborg, I; Lubman, D	1
Aksel'rod, BA; Chichenkov, TO; Kubarev, DA; Savchenkov, VA; Sivolap, I	1
Golden, SA; Sakhrani, DL	1
Castellano, M; Cervera, G; Martínez-Raga, J; Perez-Galvez, B; Sabater, A	1
Freye, E; Levy, JV; Partecke, L	1
Gewirtz, JC; Hanes, SL; Harris, AC	1
Bespalov, A; Danysz, W; Kashkin, V; Malyshkin, A; Neznanova, O; Sukhotina, I; Zakharova, E	1
Gottheil, E; Mannelli, P; Oropeza, VC; Peoples, JF; Van Bockstaele, EJ	1
Johnson, BA	1
Bailey, KP	1
France, CP; Koek, W; McMahon, LR; Sell, SL	1
Arvidsson, J; Chahl, LA; Mizutani, A	1
Bonnet, U; Overlack, M; Schürks, M	1
Amico, MC; Morrone, LA; Palmery, M; Romanelli, L; Tucci, P; Valeri, P	1
Sterious, SN; Walker, EA	1
Chaudry, S; Daiter, J; Herman, S; Raz, B; Teplin, D; Varenbut, M; Whang, P; Yung, M; Zachos, CT	1
Burns, LH; Olmstead, MC	1
Besson, J; Broers, B; Dorogy, F; Favrat, B; Krenz, S; Muller, J; Zimmermann, G; Zullino, D; Zwahlen, A	1
Gölz, J; Grüsser, SM; Partecke, G; Platz, W; Thalemann, CN	1
Collins, ED; Heitler, NE; Kleber, HD; Whittington, RA	1
O'Connor, PG	1
Funada, M; Sato, M; Wada, K	1
Aimi, N; Horie, S; Ishikawa, H; Matsumoto, K; Murayama, T; Ponglux, D; Takayama, H; Watanabe, K	1
Freye, E; Levy, J	1
O'Brien, CP	1
Divin, MF; Ko, MC; Lee, H; Traynor, JR; Woods, JH	1
Glick, SD; Maisonneuve, IM; Panchal, V; Taraschenko, OD	1
Mannelli, P; Oropeza, V; Qian, Y; Rudoy, C; Van Bockstaele, EJ	1
Dickinson, A; Everitt, BJ; Hellemans, KG	1
Miller, MM	1
Besson, J; Favrat, B	1
Contreras, JA	1
de Jong, CJ	1
Bagherzadeh, AH; Ebrahimi-Dariani, N; Farahvash, MJ; Farhangi, E; Froutan, H; Ghofrani, H; Mansour-Ghanaei, F; Mirmomen, S; Nasiri-Toosi, M; Pourrasouli, Z; Taheri, A	1
Feldman, SR; Fleischer, AB; Kaur, M; Lang, W; Liguori, A; Rapp, SR	1
Blakeslee, A; Cooney, JL; Cooney, NL; Dubin, JA; Jatlow, P; Krishnan-Sarin, S; Makuch, R; McKee, SA; Meandzija, B; O'Malley, SS; Romano-Dahlgard, D; Wu, R	1
Cubells, JF; Tang, YL; Zhao, C; Zhao, D	1
Ott, J	1
Gottheil, E; Mannelli, P; Van Bockstaele, EJ	1
Beadles-Bohling, AS; Wiren, KM	1
Berrettini, WH; Jepson, C; Lerman, C; Lynch, KG; O'Malley, S; Patterson, F; Perkins, K; Ray, R; Rukstalis, M; Strasser, A	1
Bespalov, AY; Burakov, AM; Didenko, TY; Egorova, VY; Grinenko, AY; Ivanova, EB; Krupitsky, EM; Masalov, DV; Neznanov, NG; O'Brien, CP; Romanova, TN; Tsoy, MV; Verbitskaya, EV; Woody, GE; Zvartau, EE	1
Diehl, A; Mann, K	1
Adrian, R; Koob, GF; Solbrig, MV; Wechsler, SL	1
Doebrick, C; Kimmerling, A; Kosten, TR; Sinha, R	1
Burns, LH; Butera, PG; Friedmann, N; Moran, LV; Webster, LR; Wu, N	1
Besson, J; Camarasa, X; Khazaal, Y; Zullino, DF	1
Hutchison, KE; Kaplan, GB; MacKinnon, SV; Monti, PM; Rohsenow, DJ; Sirota, AD; Swift, RM	1
Aceto, MD; Bowman, ER; Cook, CD; Harris, LS; May, EL	1
Jatlow, P; Martin, DJ; McKee, SA; O'Malley, SS; Toll, BA	1
Koob, GF; Walker, BM	1
Dannals, RF; Frost, JJ; Kim, YK; Lee, JS; McCaul, ME; Wand, GS; Weerts, EM	1
Burakov, AM; Egorova, VY; Grinenko, AY; Kruptisky, EM; Slavina, TY; Tsoy, MV; Woody, GE; Zvartau, EE	1
Bluschke, SM; De Jong, CA; Dijkstra, BA; Krabbe, PF; van der Staak, CP	1
Crain, SM; Shen, KF	4
Fisher, DJ; Knott, VJ	1
Kumar, P; Sirohi, S; Yoburn, BC	1
Hubbard, R; Mannelli, P; Murray, HW; Patkar, AA; Peindl, K; Wu, LT	1
Bernardi, M; Caputo, F; Francini, S; Stoppo, M; Vignoli, T	1
Beck, O; Eksborg, S; Franck, J; Hammarberg, A; Jayaram-Lindström, N; Konstenius, M	1
Saitz, R	1
Ding, Z; Phillips, AG; Powell, JA; Raffa, RB; Rawls, SM; Ross, G; Stagliano, GW	1
Divin, MF; Holden Ko, MC; Traynor, JR	1
Blanc, F; Perney, P; Rigole, H	1
Arout, CA; Inturrisi, CE; Juni, A; Kest, B; Klein, G; Waxman, AR	1
Page, ME; Qian, Y; Sterling, RC; Van Bockstaele, EJ	1
Haber, PS; Lee, S; Lintzeris, N; Mabbutt, J; Scopelliti, L	1
Becker, GL; France, CP; Gerak, LR; Li, JX; McMahon, LR	1
Rawson, RA; Resnick, RB; Tennant, FS; Washton, AM	2
Extein, I; Gold, MS; Kleber, HD; Pottash, AL	1
Cerdeño Impuesto, V	1
Oishi, R; Takemori, AE	1
Extein, I; Gold, MS; Kleber, HD; Martin, D; Pottash, AC	1
Goldstein, A; Inturrisi, CE; Judson, BA	1
Gold, MS; Rea, WS	1
Dackis, CA; Gold, MS; Washton, AM	1
Dackis, CA; Gold, MS	1
Resnick, RB; Washton, AM	3
Childress, AR; McLellan, AT; O'Brien, CP	1
Arndt, IC; Evans, B; Greenstein, RA; McLellan, AT; O'Brien, CP	1
Kleber, HD; Kosten, TR	1
Charney, DS; Galloway, MP; Heninger, GR; Kleber, HD; Murberg, M; Redmond, DE; Roth, RH	1
Greenstein, RA; Resnick, E; Resnick, RB	1
Katz, RJ; Manik, CP	1
Brown, DR; Chang, EB; Field, M; Miller, RJ	1
Anggård, E; Jones, AW; Neri, A	1
Krystal, JH; Redmond, DE	1
Burks, TF; Schreier, WA	1
Krivoy, W; McLellan, AT; O'Brien, CP; Terenius, L; Wahlström, A	1
Braverman, P; Charney, DS; Heninger, GR; Kleber, HD; Murburg, M; Redmond, DE; Riordan, CE; Sternberg, DE	1
Bree, MP; Mello, NK; Mendelson, JH	1
Bass, P; Goldberg, LI; Merz, H; Russell, J; Schuster, CR	1
Coyle-Perkins, G; Grabowski, J; Greenstein, RA; Long, M; McLellan, AT; O'Brien, CP; Vittor, A; Woody, GE	1
Goldstein, A; Himmelberger, DU; Judson, BA	1
Bhargava, HN; House, RV; Thomas, PT; Thorat, SN	1
Brodsky, M; Inturrisi, CE; Rasmussen, K	1
Hoffer, PB; Krystal, JH; McMahon, TJ; O'Connor, PG; Rosen, MI; Sullivan, M; Thomas, HM; van Dyck, CH; Wallace, EA; Woods, SW	1
Almeida, OF; Bartl, C; Shippenberg, TS; Spanagel, R	1
Wirschubsky, ZG	1
Brent, PJ; Cantarell, PA; Chahl, LA; Kavanagh, C	1
Bailey, MD; Bhargava, HN; Bozek, PS; Gerk, PM; Ko, KH; Matwyshyn, GA; Simko, RJ; Thorat, SN	1
Bhargava, HN; Matwyshyn, GA; Reddy, PL; Thorat, SN	1
Gossop, M; Legarda, JJ	1
Ho, IK; Hoskins, B; Jaw, SP; Makimura, M; Oh, KW	2
Ehrenreich, H; Poser, W	1
Ho, IK; Hoskins, B; Jaw, SP; Makimura, M	1
Miyamoto, Y; Takemori, AE	1
Miyamoto, Y; Portoghese, PS; Takemori, AE	1
Ho, IK; Hoskins, B; Jaw, SP	1
Amico, MC; Morrone, LA; Romanelli, L; Valeri, P	1
Cutler, R; Fishbain, DA; Rosomoff, HL	1
Galloway, G	1
Gold, MS	1
Chaudhry, H; Hofmann, P; Loimer, N	1
Bauman, M; Bullen, BA; Evans, WJ; Henley, K; McArthur, JW; Pehrson, J; Skrinar, GS; Turnbull, BA; Turner, A	1
Chami, TN; Cheskin, LJ; Jaffe, JH; Johnson, RE	1
Feyerabend, C; Russell, MA; Stapleton, JA; Sutherland, G	1
Coderre, TJ; Fundytus, ME; Schiller, PW; Shapiro, M; Weltrowska, G	1
Greenwood, J; Seivewright, NA	1
Nestler, EJ; Nye, HE	1
Bigelow, GE; Eissenberg, T; Greenwald, MK; Johnson, RE; Liebson, IA; Stitzer, ML	1
Basbaum, AI; Detweiler, DJ; Rohde, DS	1
Chahl, LA; Herdegen, T; Leah, J; Lynch-Frame, AM; Trueman, L	1
Funada, M; Schutz, CG; Shippenberg, TS	1
Barr, GA; Jones, KL	3
Diana, M; Gessa, GL; Muntoni, AL	1
Gahn, LG; Sevarino, KA	1
Feng, YZ; Ho, IK; Rockhold, RW; Tokuyama, S; Zhang, T; Zhu, H	1
Bhargava, HN; Thorat, SN	1
Hitz, S; Jackson, IM; Lechan, RM; Légrádi, G; Nillni, EA; Rand, WM	1
Bartter, T; Gooberman, LL	1
Aghajanian, GK; Kendrick, WT; Kogan, JH; Rasmussen, K	1
Capodano, RJ; Gaeta, TJ; Spevack, TA	1
Javelle, N; Lambás-Señas, L; Renaud, B	1
Stephenson, J	1
Spanagel, R; Zieglgänsberger, W	1
Castelli, MP; Diaz, G; Fadda, P; Gessa, GL; Mameli, M; Melis, M	1
Ho, IK; Hoshi, K; Ma, T; Oh, S	1
Bristow, LJ; Hogg, JE; Hutson, PH	1
Paronis, CA; Woods, JH	1
Huber, A; Ling, W; McCann, MJ; Miotto, K; Rawson, RA; Shoptaw, S	1
Barr, GA; Goodwin, GA	1
Cohen, H; Kotler, M; Rabinowitz, J; Tarrasch, R	1
Rumball, D; Williams, J	1
Carroll, KM; Kosten, TR; O'Connor, PG; Rounsaville, BJ; Schottenfeld, RS; Shi, JM	1
Miller, NS; Smith, DE	1
Kranzler, HR	1
Feng, Y; Ho, IK; Rockhold, RW	1
Alvarez, M; Cabré, L; Carrasco, G; Costa, J; Hernández, E; Molina, R; Puiggrós, A; Seoane, A; Sobrepere, G	1
Fawcett, JP; Morgan, NC; Woods, DJ	1
Kosten, TR; O'Connor, PG	1
Dyer, C	1
Basbaum, AI; Rohde, DS	1
Barr, GA; Hamowy, AS; Hutchings, DE; Liu, PY; Wang, S; Zmitrovich, A	1
Berkowitz, R; Hoffman, WE; McDonald, T	2
Bertschy, G; Cucchia, AT; Ferrero, F; Monnat, M; Spagnoli, J	1
Dhatt, R; Tejwani, GA; Wewers, ME	1
Hirtl, C; Pfab, R; Zilker, T	1
Colby, SM; Gnys, M; Hutchison, KE; Monti, PM; Niaura, RS; Rohsenow, DJ; Sirota, AD; Swift, RM	1
Rasmussen, K; Vandergriff, J	1
Behm, FM; Brauer, LH; Patel, P; Rose, JE; Westman, EC	1
Berkowitz, R; Cooke, B; Cunningham, F; Hoffman, WE; McDonald, T	1
Aston-Jones, G; Delfs, JM; Druhan, J; Zhu, Y	1
Amico, MC; Mattioli, F; Morrone, LA; Romanelli, L; Valeri, P	1
Hall, WD; Wodak, A	1
Bammer, G; Bell, JR; Masterman, SC; Mattick, RP; Morris, A; Young, MR	1
Barelli, A; De Giacomo, M; Gaspari, R; Mannelli, P; Stefanelli, A	1
Chiang, CT; Demuth, KL; Hoover, DR; Montoya, ID; Preston, KL; Umbricht, A	1
Cullen, DJ; Dwyer, MJ; Gold, CG; Gonzales, S; Houtmeyers, D	1
De Giacomo, M; De Risio, S; Janiri, L; Mannelli, P; Pozzi, G	1
Alvaro, JD; Chen, YL; Duman, RS; Iredale, PA; Lee, Y; Terwilliger, R	1
Spanagel, R	1
Foss, JF; Karrison, T; Moss, J; O'Connor, M; Osinski, J; Roizen, MF; Yuan, CS	1
Dekker, LR; Jones, EA	1
Cole, JC; Little, HJ; Littleton, JM	1
Hensel, M; Kox, WJ	1
Bocchi, C; Delsignore, R; Fontanesi, B; Gerra, G; Rustichelli, P; Timpano, M; Zaimovic, A; Zambelli, U	1
Belozertseva, IV; Bespalov, AY; Danysz, W	1
Hensel, M; Kox, WJ; Wolter, S	1
Abels, I; Albanese, AP; Eustace, JC; Field, JM; Gevirtz, C; Oppenheim, B	1
Conte, G; De Risio, S; Pozzi, G	1
Fiellin, DA; O'Connor, PG	1
Parikh, K; Picciotto, MR; Thome, J; Zachariou, V	1
Bearn, J; Buntwal, N; Gossop, M; Strang, J	1
King, AC; Meyer, PJ	1
Aston-Jones, G; Druhan, JP; Walters, CL	2
Zhang, HT	1
Hölter, SM; Spanagel, R	1
Koob, GF	1
Cui, CL; Han, JS; Wu, LZ	1
Boto, I; Gomes, PC; Henriques, V; Macedo, TR; Morgadinho, MT; Nunes, SV; Pacheco, F; Pinto, CM; Ramalheira, C; Relvas, J; Ruis, GR; Vale, LL; Ventura, M	1
Georges, F; Le Moine, C; Stinus, L	1
Breiter, H; D'Ambra, MN; Elman, I; Gastfriend, DR; Kane, M; Krause, S; Morris, R; Tuffy, L	1
Schwab, CA; Wright, DA	1
Colby, SM; Hutchison, KE; Kaplan, GB; Monti, PM; Rohsenow, DJ; Swift, RM	1
Yui, K	1
Brady, KT; Malcolm, R; Myrick, H	1
Brown, R; Lo, R	1
Barr, GA; Zhu, H	1
Bilsky, EJ; Raehal, KM; Sadée, W; Wang, D	1
Korpi, E; Seppälä, T	1
Bristow, K; Clark, N; Meek, R	1
Boyce, SH; Quigley, MA	1
Hamilton, RJ; Hoffman, RS; Howland, MA; Hung, OL; Lewin, NL; Nelson, LS; Olmedo, RE; Perrone, J; Shah, S	1
Atias, S; Cohen, H; Rabinowitz, J	1
Hulse, GK; O'Neill, G	1
Lechan, RM; Lee, A; Legradi, G; Nillni, EA	1
Barrot, M; Duman, RS; Gilden, L; Impey, S; Nestler, EJ; Shaw-Lutchman, TZ; Storm, D; Wallace, T; Zachariou, V	1
Alvarez, CE; Bascarán, MT; Bobes, J; Brewer, C; Carreño, JE; San Narciso, GI; Sánchez del Río, J	1
France, CP; Sell, SL	1
Resnick, RB; Volavka, J	1
Greenstein, R; O'Brien, C	1
Rawson, RA; Resnick, RB; Washton, AM	1
Ary, M; Chesarek, W; Lomax, P; Sorensen, SM	1
Greenstein, R; O'Brien, CP; Woody, GE	1
Kestenbaum, RS; Resnick, RB; Thomas, MA; Washton, AM	1
Wikler, A	2
Greenstein, R; O'Brien, CP; Ternes, J; Woody, GE	1
Greenstein, R; O'Brien, CP; Ternes, J; Testa, T	1
Julius, DA	1
Costa, E; Fratta, W; Hong, J; Yang, HY	1
Gilbert, PE; Martin, WR	1
Gellert, VF; Holtzman, SG	1
Gitlin, M; Rosenblatt, M	1
Colombel, MC; Jacob, J; Tremblay, E	1
Kestenbaum, RS; Poole, D; Resnick, RB; Washton, A	1
Bläsig, J; Herz, A; Höllt, V; Paschelke, G	1
Ary, M; Lomax, P	1
Chen, RC; Ho, AK	1
Baraban, JM; Bhat, RV; Cole, AJ; Worley, PF	1
Kleber, HD; Kosten, TR; Morgan, C	2
Duman, RS; Hayward, MD; Nestler, EJ	1
Aghajanian, GK; Krystal, JH; Rasmussen, K	1
Senft, RA	1
Fuller, RW; Ornstein, PL; Perry, KW; Rasmussen, K; Stockton, ME; Swinford, RM	1
Goosen, C; Kornet, M; Van Ree, JM	1
Lenz, K; Loimer, N; Presslich, O; Schmid, R	2
Caballero, L; Iruela, LM; Oliveros, SC	1
Aghajanian, GK; Beitner-Johnson, DB; Krystal, JH; Nestler, EJ; Rasmussen, K	1
Misawa, M; Suzuki, T	1
Fukagawa, Y; Misawa, M; Nagase, H; Suzuki, T	1
Aranow, JS; Kelsey, JE; Matthews, RT	1
Adams, JU; Holtzman, SG	1
Charney, DS; Kleber, HD; Kosten, TR; Krystal, JH; Morgan, CH; Price, LH	2
Bronson, ME; Sparber, SB	1
Costa, E; Mocchetti, I; Ritter, A	1
Falls, WA; Kelsey, JE	1
France, CP; Woods, JH	1
Fukagawa, Y; Katz, JL; Suzuki, T	1
Aghajanian, GK; Rasmussen, K	1
Drummond, DC; Turkington, D	1
Meyer, RE	1
Kotlińska, J; Langwiński, R	1
Eriksson, I; McLellan, AT; Nyberg, F; O'Brien, CP; Terenius, LY	1
Childress, AR; McLellan, AT	1
Kleber, HD; Kosten, TR; Kreek, MJ; Ragunath, J	1
Zagon, IS	1
Kleber, HD	1
Gilbert, PE; Jasinski, DR; Martin, CD; Martin, WR	1
Gossop, M	1
Losowsky, MS; Thornton, JR	1
Bailey, C; Brewer, C; Rezae, H	1
Chan, WC; Gintzler, AR; Sharma, TR	1
Agren, H	1
Mucha, RF	1
Gaspari, J; Kleber, HD; Kosten, T; Riordan, CE; Topazian, M	1
Charney, DS; Heninger, GR; Kleber, HD	1
Aceto, MD; Dewey, WL; Portoghese, PS; Takemori, AE	1
Elsworth, JD; Redmond, DE; Roth, RH	1
de Feo, G; Mazzanti, G; Piccinelli, D	2
Dzoljic, MR; Ukponmwan, OE; vd Poel-Heisterkamp, AL	1
Gmerek, DE; Woods, JH	1
Friedman, JG; Grossman, DJ; Schecter, AJ	1

Reviews

59 review(s) available for naltrexone and Drug Withdrawal Symptoms

Article	Year
Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting. Hospital practice (1995), 2022, Volume: 50, Issue:4 Topics: Analgesics, Opioid; Antiemetics; Benzodiazepines; Buprenorphine; Hospitals; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; United States	2022
Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care. The Cochrane database of systematic reviews, 2022, 09-15, Volume: 9 Topics: Adult; Analgesics, Opioid; Child; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Neoplasms; Opioid-Induced Constipation; Oxycodone; Palliative Care; Quaternary Ammonium Compounds; Substance Withdrawal Syndrome	2022
Adjunctive memantine for opioid use disorder treatment: A systematic review. Journal of substance abuse treatment, 2019, Volume: 107 Topics: Analgesics, Opioid; Buprenorphine; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Memantine; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Outcome Assessment, Health Care; Substance Withdrawal Syndrome	2019
Medications Development for Treatment of Opioid Use Disorder. Cold Spring Harbor perspectives in medicine, 2021, 01-04, Volume: 11, Issue:1 Topics: Analgesics, Opioid; Buprenorphine; Choice Behavior; Drug Development; Evidence-Based Medicine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Receptors, Opioid, mu; Self Administration; Substance Withdrawal Syndrome; Treatment Outcome	2021
Opioid Withdrawal Precipitated by Long-Acting Antagonists. The Journal of emergency medicine, 2020, Volume: 58, Issue:2 Topics: Drug Combinations; Emergency Service, Hospital; Humans; Morphine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome	2020
Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management. Molecules (Basel, Switzerland), 2020, Sep-11, Volume: 25, Issue:18 Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Humans; Ligands; Macaca mulatta; Mice; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain; Pain Management; Receptors, Opioid, mu; Signal Transduction; Substance Withdrawal Syndrome	2020
Pharmacotherapies for the Treatment of Alcohol Use Disorders During Pregnancy: Time to Reconsider? Drugs, 2021, Volume: 81, Issue:7 Topics: Acamprosate; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Animals; Comorbidity; Disulfiram; Female; Fetal Alcohol Spectrum Disorders; Humans; Naltrexone; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Substance Withdrawal Syndrome	2021
Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians. Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:6 Topics: Alcoholism; Analgesics, Opioid; Animals; Drug Interactions; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk Factors; Substance Withdrawal Syndrome	2017
Opioid antagonists with minimal sedation for opioid withdrawal. The Cochrane database of systematic reviews, 2017, 05-29, Volume: 5 Topics: Adrenergic alpha-Agonists; Clonidine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Non-Randomized Controlled Trials as Topic; Opioid-Related Disorders; Prospective Studies; Randomized Controlled Trials as Topic; Severity of Illness Index; Substance Withdrawal Syndrome	2017
Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials. PloS one, 2017, Volume: 12, Issue:8 Topics: Disruptive, Impulse Control, and Conduct Disorders; Humans; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders	2017
CE: Acute Pain Management for People with Opioid Use Disorder. The American journal of nursing, 2018, Volume: 118, Issue:10 Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Nurse's Role; Opiate Substitution Treatment; Opioid-Related Disorders; Pain Management; Palliative Care; Substance Withdrawal Syndrome	2018
Medications for substance use disorders. Social work in public health, 2013, Volume: 28, Issue:3-4 Topics: Alcohol Deterrents; Alcoholism; Analgesics, Opioid; Behavior Therapy; Behavior, Addictive; Buprenorphine; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Disorder	2013
Rapid opiate detoxification and antagonist induction under general anaesthesia or intravenous sedation is humane, sometimes essential and should always be an option. Three illustrative case reports involving diabetes and epilepsy and a review of the liter Journal of psychopharmacology (Oxford, England), 2014, Volume: 28, Issue:1 Topics: Administration, Intravenous; Adult; Anesthesia, General; Bioethical Issues; Diabetes Complications; Epilepsy; Heroin Dependence; Humans; Hypnotics and Sedatives; Male; Naltrexone; Narcotic Antagonists; Remission Induction; Substance Withdrawal Syndrome	2014
[New treatment options for alcohol dependence]. MMW Fortschritte der Medizin, 2013, May-02, Volume: 155, Issue:8 Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; Psychotherapy; Secondary Prevention; Socioenvironmental Therapy; Substance Withdrawal Syndrome; Taurine; Topiramate	2013
[Depression in alcohol addicted patients]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:7 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depressive Disorder; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Taurine	2015
[Pharmacological therapies for alcohol use disorder in Japan]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:9 Topics: Acamprosate; Alcohol-Related Disorders; Alcohols; Humans; Japan; Naltrexone; Substance Withdrawal Syndrome; Taurine	2015
Pharmacotherapy for Substance Use Disorders. The Medical clinics of North America, 2016, Volume: 100, Issue:4 Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline	2016
Unintentional rapid opioid detoxification: case report. Psychiatria Danubina, 2009, Volume: 21, Issue:1 Topics: Adult; Consciousness Disorders; Critical Care; Diazepam; Drug Interactions; Emergency Service, Hospital; Epilepsy, Generalized; Humans; Illicit Drugs; Infusions, Intravenous; Male; Naltrexone; Narcotic Antagonists; Narcotics; Neurologic Examination; Opioid-Related Disorders; Private Practice; Substance Abuse Detection; Substance Withdrawal Syndrome	2009
Opioid antagonists with minimal sedation for opioid withdrawal. The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4 Topics: Adrenergic alpha-Agonists; Clinical Trials as Topic; Clonidine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome	2009
Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. The Cochrane database of systematic reviews, 2010, Jan-20, Issue:1 Topics: Anesthetics; Humans; Hypnotics and Sedatives; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome	2010
The pharmacological treatment of opioid addiction--a clinical perspective. European journal of clinical pharmacology, 2010, Volume: 66, Issue:6 Topics: Adrenergic Agonists; Analgesics, Opioid; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Social Support; Substance Withdrawal Syndrome	2010
Heroin anticraving medications: a systematic review. The American journal of drug and alcohol abuse, 2010, Volume: 36, Issue:6 Topics: Buprenorphine; Heroin; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome	2010
Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. Current drug abuse reviews, 2012, Volume: 5, Issue:1 Topics: Biological Availability; Buprenorphine; Chemistry, Pharmaceutical; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome	2012
Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. The American journal of drug and alcohol abuse, 2012, Volume: 38, Issue:3 Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clinical Protocols; Clonidine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome	2012
Maintenance medication for opiate addiction: the foundation of recovery. Journal of addictive diseases, 2012, Volume: 31, Issue:3 Topics: Analgesics, Opioid; Buprenorphine; Humans; Long-Term Care; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome	2012
Medications development for opioid abuse. Cold Spring Harbor perspectives in medicine, 2013, Jan-01, Volume: 3, Issue:1 Topics: Analgesics, Opioid; Buprenorphine; Choice Behavior; Endocannabinoids; Evidence-Based Medicine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neuroglia; Opioid-Related Disorders; Receptors, Opioid, mu; Reinforcement, Psychology; Self Administration; Substance Withdrawal Syndrome; Treatment Outcome	2013
Therapy and supportive care of alcoholics: guidelines for practitioners. Best practice & research. Clinical gastroenterology, 2003, Volume: 17, Issue:4 Topics: Alcohol-Related Disorders; Alcoholics Anonymous; Alcoholism; Ambulatory Care Facilities; Counseling; Day Care, Medical; Humans; Motivation; Naltrexone; Practice Guidelines as Topic; Psychotherapy, Brief; Secondary Prevention; Substance Abuse Treatment Centers; Substance Withdrawal Syndrome; Temperance	2003
An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:9 Topics: Alcohol Deterrents; Alcoholism; Anticonvulsants; Behavior, Addictive; Biomarkers; Drug Therapy, Combination; Humans; Naltrexone; Serotonin Agents; Substance Withdrawal Syndrome	2004
Pharmacological treatments for substance use disorders. Journal of psychosocial nursing and mental health services, 2004, Volume: 42, Issue:8 Topics: Adrenergic beta-Antagonists; Alcohol Deterrents; Anti-Anxiety Agents; Benzodiazepines; Buprenorphine; Disulfiram; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neurobiology; Neuropharmacology; Psychopharmacology; Substance Withdrawal Syndrome; Substance-Related Disorders	2004
Opiate addiction in China: current situation and treatments. Addiction (Abingdon, England), 2006, Volume: 101, Issue:5 Topics: Buprenorphine; China; Clonidine; Drugs, Chinese Herbal; HIV Infections; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Abuse, Intravenous; Substance Withdrawal Syndrome; Sympatholytics	2006
Antagonist treatment of opioid withdrawal translational low dose approach. Journal of addictive diseases, 2006, Volume: 25, Issue:2 Topics: Animals; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome	2006
[Pharmacological relapse prevention in alcohol and tobacco dependence]. Der Internist, 2007, Volume: 48, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; Humans; Naltrexone; Nicotine; Psychotherapy; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Taurine; Tobacco Use Disorder	2007
Treatment of alcohol and other drug dependence. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2007, Volume: 13, Issue:11 Suppl 2 Topics: Alcoholism; Behavior, Addictive; Comorbidity; Humans; Methadone; Naltrexone; Psychotherapy; Substance Withdrawal Syndrome; Substance-Related Disorders; Treatment Outcome	2007
[Alcohol dependence: diagnosis and treatment]. La Revue de medecine interne, 2008, Volume: 29, Issue:4 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Disulfiram; Humans; Motivation; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Taurine	2008
[Narcotic withdrawal syndrome. Therapeutic methods]. Revista clinica espanola, 1982, Oct-15, Volume: 167, Issue:1 Topics: Acupuncture Therapy; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Analgesia; Brain; Central Nervous System Agents; Clonidine; Endorphins; Humans; Methadone; Naloxone; Naltrexone; Narcotics; Receptors, Opioid; Substance Withdrawal Syndrome; Substance-Related Disorders	1982
The role of endorphins in opiate addiction, opiate withdrawal, and recovery. The Psychiatric clinics of North America, 1983, Volume: 6, Issue:3 Topics: Alcoholism; Brain; Endorphins; Humans; Hypothalamo-Hypophyseal System; Locus Coeruleus; Naltrexone; Norepinephrine; Opioid-Related Disorders; Substance Withdrawal Syndrome	1983
The sequential use of clonidine and naltrexone in the treatment of opiate addicts. Advances in alcohol & substance abuse, 1984,Spring, Volume: 3, Issue:3 Topics: Adult; Baclofen; Clonidine; Drug Therapy, Combination; Electric Stimulation Therapy; Endorphins; Ethanol; Female; Humans; Locus Coeruleus; Male; Methyldopa; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	1984
New insights and treatments: opiate withdrawal and cocaine addiction. Clinical therapeutics, 1984, Volume: 7, Issue:1 Topics: Brain Chemistry; Clonidine; Cocaine; Dopamine; Humans; Methadone; Naltrexone; Norepinephrine; Substance Withdrawal Syndrome; Substance-Related Disorders	1984
Opiate detoxification protocols. A clinical manual. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1993, Volume: 5, Issue:1 Topics: Administration, Cutaneous; Clinical Protocols; Clonidine; Codeine; Female; Humans; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Psychiatric Status Rating Scales; Receptors, Opioid; Substance Withdrawal Syndrome	1993
Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine. The Psychiatric clinics of North America, 1993, Volume: 16, Issue:1 Topics: Animals; Buprenorphine; Clonidine; Humans; Locus Coeruleus; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	1993
What is important in drug misuse treatment? Lancet (London, England), 1996, Feb-10, Volume: 347, Issue:8998 Topics: Buprenorphine; Clonidine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Substance-Related Disorders; United Kingdom	1996
Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends in pharmacological sciences, 1997, Volume: 18, Issue:2 Topics: Acamprosate; Alcoholism; Animals; Behavior, Animal; Calcium Channels; Disease Models, Animal; Humans; Naltrexone; Narcotic Antagonists; Neurons; Rats; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Recurrence; Substance Withdrawal Syndrome; Synaptic Transmission; Taurine	1997
Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study. Drug and alcohol dependence, 1997, Aug-25, Volume: 47, Issue:2 Topics: Anesthesia, General; Clonidine; Follow-Up Studies; Humans; Israel; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Recurrence; Substance Withdrawal Syndrome; Treatment Outcome	1997
The integration of pharmacotherapy and nonpharmacotherapy. Journal of addictive diseases, 1997, Volume: 16, Issue:4 Topics: Alcohol Deterrents; Behavior, Addictive; Combined Modality Therapy; Disease Susceptibility; Disulfiram; Drug Interactions; Humans; Naltrexone; Narcotic Antagonists; Patient Acceptance of Health Care; Psychotherapy; Psychotropic Drugs; Substance Withdrawal Syndrome; Substance-Related Disorders; Treatment Outcome	1997
Treatment of alcohol dependence. Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 1997, Volume: 3, Issue:3 Topics: Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Recurrence; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome	1997
Rapid and ultrarapid opioid detoxification techniques. JAMA, 1998, Jan-21, Volume: 279, Issue:3 Topics: Clinical Trials as Topic; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Research Design; Substance Withdrawal Syndrome	1998
Pharmacologic treatment of heroin-dependent patients. Annals of internal medicine, 2000, Jul-04, Volume: 133, Issue:1 Topics: Analgesics, Opioid; Buprenorphine; Counseling; Heroin Dependence; Humans; Mental Disorders; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Physician's Role; Substance Withdrawal Syndrome	2000
Animal models of craving for ethanol. Addiction (Abingdon, England), 2000, Volume: 95 Suppl 2 Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Operant; Disease Models, Animal; Drug Tolerance; Motivation; Naltrexone; Narcotic Antagonists; Predictive Value of Tests; Rats; Reinforcement, Psychology; Reproducibility of Results; Substance Withdrawal Syndrome; Taurine	2000
New developments in the pharmacotherapy of alcohol dependence. The American journal on addictions, 2001, Volume: 10, Issue:s1 Topics: Acamprosate; Adjuvants, Anesthesia; Alcohol Deterrents; Alcoholism; Anticonvulsants; Buspirone; Carbamazepine; Drug Therapy; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Ritanserin; Serotonin Agents; Sodium Oxybate; Substance Withdrawal Syndrome; Taurine; Valproic Acid; Vigabatrin	2001
The physical and psychosocial consequences of opioid addiction: an overview of changes in opioid treatment. The Australian and New Zealand journal of mental health nursing, 2000, Volume: 9, Issue:2 Topics: Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome	2000
[Alcohol--mechanism of action, interactions and treatment of alcohol abuse]. Duodecim; laaketieteellinen aikakauskirja, 1998, Volume: 114, Issue:10 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Interactions; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Taurine	1998
Methadone maintenance and narcotic blocking drugs. Appendix. The International journal of the addictions, 1977, Volume: 12, Issue:7 Topics: Administration, Oral; Cyclazocine; Drug Tolerance; Heroin Dependence; Humans; Injections, Subcutaneous; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Research; Substance Withdrawal Syndrome	1977
Clinical pharmacology of narcotic antagonists. Annals of the New York Academy of Sciences, 1978, Volume: 311 Topics: Animals; Conditioning, Psychological; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders	1978
[Clonidine-naltrexone: a new technic for the detoxification of opiate addicts]. Medicina clinica, 1990, Nov-10, Volume: 95, Issue:16 Topics: Clonidine; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome	1990
Prospects for a rational pharmacotherapy of alcoholism. The Journal of clinical psychiatry, 1989, Volume: 50, Issue:11 Topics: Alcoholism; Animals; Benzodiazepines; Cognition; Ethanol; Humans; Naltrexone; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome	1989
Aversive therapies for substance abuse: do they work? Journal of substance abuse treatment, 1985, Volume: 2, Issue:3 Topics: Apomorphine; Aversive Therapy; Conditioning, Classical; Desensitization, Psychologic; Electroshock; Emetine; Extinction, Psychological; Humans; Naltrexone; Patient Compliance; Research Design; Substance Withdrawal Syndrome; Substance-Related Disorders; Succinylcholine	1985
Opioids and development: new lessons from old problems. NIDA research monograph, 1985, Volume: 60 Topics: Animals; Brain; Child Behavior; Child Development; Dose-Response Relationship, Drug; Female; Fetus; Humans; Naltrexone; Narcotics; Opioid-Related Disorders; Pregnancy; Rats; Receptors, Opioid; Substance Withdrawal Syndrome	1985
Clonidine and the treatment of the opiate withdrawal syndrome. Drug and alcohol dependence, 1988, Volume: 21, Issue:3 Topics: Clonidine; Humans; Hypotension; Methadone; Naltrexone; Narcotics; Substance Withdrawal Syndrome	1988
Clonidine treatment of the opiate withdrawal syndrome. A review of clinical trials of a theory. Acta psychiatrica Scandinavica. Supplementum, 1986, Volume: 327 Topics: Adrenergic Fibers; Animals; Antidepressive Agents, Tricyclic; Brain; Clinical Trials as Topic; Clonidine; Dextropropoxyphene; Drug Therapy, Combination; Heroin Dependence; Humans; Locus Coeruleus; Methadone; Morphine; Naltrexone; Narcotics; Norepinephrine; Rats; Substance Withdrawal Syndrome	1986

Trials

79 trial(s) available for naltrexone and Drug Withdrawal Symptoms

Article	Year
Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study. The American journal on addictions, 2019, Volume: 28, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Chemoprevention; Clonidine; Craving; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Intention to Treat Analysis; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Pilot Projects; Recurrence; Secondary Prevention; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult	2019
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens. The American journal on addictions, 2020, Volume: 29, Issue:4 Topics: Adult; Buprenorphine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Monitoring; Drug Substitution; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome	2020
Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial. Drug and alcohol dependence, 2021, 02-01, Volume: 219 Topics: Adult; Animals; Benzazepines; Buprenorphine; Delayed-Action Preparations; Female; Humans; Injections; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Substance Withdrawal Syndrome; Swine	2021
Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial. JAMA psychiatry, 2017, 09-01, Volume: 74, Issue:9 Topics: Adult; Analgesics; Analgesics, Opioid; Buprenorphine; Clonidine; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome; Tramadol; Treatment Outcome; Young Adult	2017
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. Drug and alcohol dependence, 2018, 06-01, Volume: 187 Topics: Adult; Ambulatory Care; Buprenorphine; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Patient Transfer; Substance Withdrawal Syndrome	2018
Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder. Journal of psychiatry & neuroscience : JPN, 2018, Volume: 43, Issue:4 Topics: Adult; Craving; Cues; Delayed-Action Preparations; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neuroimaging; Nucleus Accumbens; Opioid-Related Disorders; Photic Stimulation; Prefrontal Cortex; Substance Withdrawal Syndrome; Young Adult	2018
Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone. The American journal on addictions, 2018, Volume: 27, Issue:6 Topics: Adult; Buprenorphine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Outpatients; Severity of Illness Index; Substance Withdrawal Syndrome; Symptom Assessment	2018
Smoking and opioid detoxification: behavioral changes and response to treatment. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2013, Volume: 15, Issue:10 Topics: Adult; Double-Blind Method; Female; Humans; Male; Naltrexone; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder	2013
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. Drug and alcohol dependence, 2014, May-01, Volume: 138 Topics: Adult; Buprenorphine; Craving; Delayed-Action Preparations; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Substance Withdrawal Syndrome; Young Adult	2014
A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:2 Topics: Adult; Affect; Alcoholism; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Treatment Outcome	2015
Naltrexone-facilitated buprenorphine discontinuation: a feasibility trial. Journal of substance abuse treatment, 2015, Volume: 53 Topics: Administration, Oral; Adult; Buprenorphine; Drug Administration Schedule; Feasibility Studies; Female; Humans; Injections; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome	2015
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug and alcohol dependence, 2015, Sep-01, Volume: 154 Topics: Adult; Cannabinoids; Delayed-Action Preparations; Double-Blind Method; Dronabinol; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Substance Withdrawal Syndrome; Young Adult	2015
Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial. Clinical pharmacology and therapeutics, 2016, Volume: 100, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult	2016
Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. Journal of psychopharmacology (Oxford, England), 2009, Volume: 23, Issue:2 Topics: Adult; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Piperazines; Quinolones; Secondary Prevention; Substance Withdrawal Syndrome	2009
Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. Addiction biology, 2009, Volume: 14, Issue:2 Topics: Adult; Analgesics, Opioid; Community Mental Health Services; Disruptive, Impulse Control, and Conduct Disorders; Double-Blind Method; Drug Administration Schedule; Female; Humans; Inactivation, Metabolic; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Program Development; Substance Withdrawal Syndrome	2009
Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. The American journal of psychiatry, 2008, Volume: 165, Issue:11 Topics: Adult; Amphetamine; Amphetamine-Related Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Secondary Prevention; Substance Abuse Detection; Substance Withdrawal Syndrome; Survival Analysis; Treatment Outcome	2008
Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:9 Topics: Adult; Alcohol Withdrawal Delirium; Alcohol-Related Disorders; Anticonvulsants; Anxiety; Calcium Channel Blockers; Double-Blind Method; Female; gamma-Aminobutyric Acid; Hostility; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Pregabalin; Severity of Illness Index; Substance Withdrawal Syndrome	2010
Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology. PloS one, 2009, Volume: 4, Issue:4 Topics: Double-Blind Method; Female; Fibromyalgia; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid Peptides; Pain Measurement; Pain Threshold; Placebos; Substance Withdrawal Syndrome; Treatment Outcome	2009
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addictive behaviors, 2010, Volume: 35, Issue:3 Topics: Adult; Bupropion; Cotinine; Counseling; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Weight Gain	2010
Challenges to antagonist blockade during sustained-release naltrexone treatment. Addiction (Abingdon, England), 2010, Volume: 105, Issue:9 Topics: Adult; Crime; Delayed-Action Preparations; Depression; Drug Implants; Drug Overdose; Euphoria; Female; Hair; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Patient Compliance; Psychiatric Status Rating Scales; Secondary Prevention; Substance Abuse Detection; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult	2010
Gabapentin combined with naltrexone for the treatment of alcohol dependence. The American journal of psychiatry, 2011, Volume: 168, Issue:7 Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug Therapy, Combination; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Secondary Prevention; Substance Withdrawal Syndrome; Treatment Outcome	2011
Problem drinking and low-dose naltrexone-assisted opioid detoxification. Journal of studies on alcohol and drugs, 2011, Volume: 72, Issue:3 Topics: Adult; Alcohol Drinking; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Severity of Illness Index; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult	2011
Methylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension study. Journal of pain & palliative care pharmacotherapy, 2011, Volume: 25, Issue:2 Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Constipation; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Quaternary Ammonium Compounds; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome	2011
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug and alcohol dependence, 2011, Dec-01, Volume: 119, Issue:1-2 Topics: Adult; Disease Progression; Dopamine Agents; Double-Blind Method; Female; Humans; Male; Medication Adherence; Memantine; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Placebos; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Substance Abuse Detection; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Young Adult	2011
The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal. The American journal of drug and alcohol abuse, 2012, Volume: 38, Issue:3 Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Clonidine; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome	2012
A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. Drug and alcohol dependence, 2002, Sep-01, Volume: 68, Issue:1 Topics: Adrenergic alpha-Agonists; Adult; Anesthesia, General; Clonidine; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Risk Factors; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome	2002
Neuroendocrine and behavioural responses to opioid receptor-antagonist during heroin detoxification: relationship with personality traits. International clinical psychopharmacology, 2003, Volume: 18, Issue:5 Topics: Adult; Blood Pressure; Comorbidity; Epinephrine; Heart Rate; Heroin Dependence; Humans; Hydrocortisone; Male; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Norepinephrine; Personality Disorders; Substance Withdrawal Syndrome; Treatment Outcome	2003
[Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention]. Vestnik Rossiiskoi akademii meditsinskikh nauk, 2003, Issue:10 Topics: Adult; Amitriptyline; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Double-Blind Method; Drug Therapy, Combination; Heroin Dependence; Humans; Mood Disorders; Naltrexone; Narcotic Antagonists; Patient Compliance; Placebos; Recurrence; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome	2003
Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity. Drug and alcohol review, 2003, Volume: 22, Issue:4 Topics: Adolescent; Adult; Female; Heroin; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Severity of Illness Index; Substance Withdrawal Syndrome; Surveys and Questionnaires	2003
Add-on gabapentin in the treatment of opiate withdrawal. Progress in neuro-psychopharmacology & biological psychiatry, 2004, Volume: 28, Issue:3 Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Female; Gabapentin; gamma-Aminobutyric Acid; Heroin; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Narcotics; Recurrence; Substance Withdrawal Syndrome	2004
Use of gabapentin for attenuation of symptoms following rapid opiate detoxification (ROD)--correlation with neurophysiological parameters--. Neurophysiologie clinique = Clinical neurophysiology, 2004, Volume: 34, Issue:2 Topics: Acetates; Adult; Amines; Anesthesia; Anesthetics, Intravenous; Cyclohexanecarboxylic Acids; Electric Stimulation; Evoked Potentials, Somatosensory; Excitatory Amino Acid Antagonists; Female; Gabapentin; gamma-Aminobutyric Acid; Heroin Dependence; Hormone Antagonists; Humans; Magnesium; Male; Median Nerve; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Potassium; Propofol; Restless Legs Syndrome; Somatostatin; Substance Withdrawal Syndrome; Water-Electrolyte Balance	2004
Opioid antagonist detoxification under anaesthesia versus traditional clonidine detoxification combined with an additional week of psychosocial support: a randomised clinical trial. Drug and alcohol dependence, 2006, Feb-01, Volume: 81, Issue:2 Topics: Adult; Algorithms; Analgesics; Anesthesia, General; Clonidine; Drug Administration Schedule; Female; Heroin Dependence; Hospitals, Psychiatric; Hospitals, Teaching; Humans; Inactivation, Metabolic; Male; Naltrexone; Narcotic Antagonists; Prospective Studies; Recurrence; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome	2006
A new approach to preventing relapse in opiate addicts: a psychometric evaluation. Biological psychology, 2006, Volume: 71, Issue:3 Topics: Administration, Oral; Adult; Affect; Delayed-Action Preparations; Drug Administration Schedule; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Outcome and Process Assessment, Health Care; Personality Inventory; Psychometrics; Secondary Prevention; Substance Withdrawal Syndrome	2006
Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA, 2005, Aug-24, Volume: 294, Issue:8 Topics: Adult; Anesthesia, General; Buprenorphine; Clonidine; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome	2005
Effect of oral naltrexone on pruritus in cholestatic patients. World journal of gastroenterology, 2006, Feb-21, Volume: 12, Issue:7 Topics: Administration, Oral; Adult; Aged; Cholestasis; Dizziness; Headache; Humans; Middle Aged; Muscle Weakness; Naltrexone; Nausea; Pain Measurement; Placebos; Pruritus; Single-Blind Method; Substance Withdrawal Syndrome; Surveys and Questionnaires	2006
Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners. Journal of the American Academy of Dermatology, 2006, Volume: 54, Issue:4 Topics: Adolescent; Adult; Beauty Culture; Behavior, Addictive; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Skin; Substance Withdrawal Syndrome; Ultraviolet Rays	2006
A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Archives of internal medicine, 2006, Mar-27, Volume: 166, Issue:6 Topics: Administration, Cutaneous; Administration, Oral; Ambulatory Care; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Linear Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires; Treatment Outcome; Weight Gain	2006
Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology, 2006, Volume: 188, Issue:3 Topics: Adaptation, Psychological; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Polymorphism, Genetic; Receptors, Opioid, mu; Reinforcement, Psychology; Risk Factors; Sex Factors; Smoking; Smoking Cessation; Substance Withdrawal Syndrome	2006
Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. Journal of substance abuse treatment, 2006, Volume: 31, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Heroin; Heroin Dependence; HIV Infections; Humans; Male; Naltrexone; Narcotic Antagonists; Psychotherapy; Russia; Secondary Prevention; Substance Abuse, Intravenous; Substance Withdrawal Syndrome	2006
Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology, 2007, Volume: 190, Issue:4 Topics: Adult; Behavior, Addictive; Clonidine; Cues; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Secondary Prevention; Stress, Psychological; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome	2007
Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. The journal of pain, 2006, Volume: 7, Issue:12 Topics: Adolescent; Adult; Aged; Analgesics; Analysis of Variance; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Low Back Pain; Male; Middle Aged; Naltrexone; Oxycodone; Pain Measurement; Substance Withdrawal Syndrome; Treatment Outcome	2006
High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking. Experimental and clinical psychopharmacology, 2007, Volume: 15, Issue:1 Topics: Administration, Cutaneous; Administration, Oral; Adult; Blood Pressure; Breath Tests; Capsules; Carbon Monoxide; Demography; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Smoking; Substance Withdrawal Syndrome; Surveys and Questionnaires; Tablets	2007
Naltrexone alteration of the nicotine-induced EEG and mood activation response in tobacco-deprived cigarette smokers. Experimental and clinical psychopharmacology, 2007, Volume: 15, Issue:4 Topics: Adult; Affect; Analysis of Variance; Blood Pressure; Double-Blind Method; Electroencephalography; Female; Heart Rate; Humans; Male; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Substance Withdrawal Syndrome; Surveys and Questionnaires	2007
Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:5 Topics: Adrenergic alpha-Agonists; Adult; Analysis of Variance; Clonidine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Psychotherapy; Substance Withdrawal Syndrome; Treatment Refusal	2007
Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:8 Topics: Adult; Aging; Amphetamine-Related Disorders; Central Nervous System Stimulants; Cross-Over Studies; Dextroamphetamine; Double-Blind Method; Endorphins; Half-Life; Humans; Hydrocortisone; Male; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Psychological Tests; Substance Withdrawal Syndrome	2008
Methadyl acetate (LAAM) in the treatment of heroin addicts. II. Double-blind comparison of gradual and abrupt detoxification. Archives of general psychiatry, 1983, Volume: 40, Issue:8 Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Methadone; Methadyl Acetate; Naltrexone; Outcome and Process Assessment, Health Care; Placebos; Substance Withdrawal Syndrome	1983
Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: evidence for noradrenergic hyperactivity. Life sciences, 1984, Sep-17, Volume: 35, Issue:12 Topics: Adult; Blood Pressure; Brain; Female; Humans; Kinetics; Male; Methadone; Methoxyhydroxyphenylglycol; Naloxone; Naltrexone; Narcotics; Norepinephrine; Substance Withdrawal Syndrome; Substance-Related Disorders	1984
Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy. Archives of general psychiatry, 1982, Volume: 39, Issue:11 Topics: Adult; Blood Pressure; Clonidine; Double-Blind Method; Drug Administration Schedule; Female; Heart Rate; Humans; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	1982
SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine. Psychiatry research, 1994, Volume: 55, Issue:4 Topics: Adult; Buprenorphine; Female; Gyrus Cinguli; Humans; Male; Naltrexone; Placebos; Regional Blood Flow; Severity of Illness Index; Substance Withdrawal Syndrome; Substance-Related Disorders; Thalamus; Tomography, Emission-Computed, Single-Photon	1994
Nalmefene enhances LH secretion in a proportion of oligo-amenorrheic athletes. Acta endocrinologica, 1993, Volume: 128, Issue:4 Topics: Adult; Amenorrhea; Analysis of Variance; Androstenedione; Dehydroepiandrosterone; Estradiol; Female; Humans; Luteinizing Hormone; Menstruation; Naltrexone; Narcotic Antagonists; Oligomenorrhea; Physical Education and Training; Pituitary Gland; Progesterone; Sports; Substance Withdrawal Syndrome; Thyrotropin; Thyroxine; Time Factors; Vagina	1993
Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Drug and alcohol dependence, 1995, Volume: 39, Issue:2 Topics: Adult; Arousal; Autonomic Nervous System; Constipation; Dose-Response Relationship, Drug; Gastrointestinal Motility; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Neurologic Examination; Opioid-Related Disorders; Substance Withdrawal Syndrome	1995
Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology, 1995, Volume: 120, Issue:4 Topics: Adult; Affect; Behavior; Female; Humans; Male; Naltrexone; Nicotine; Placebo Effect; Reinforcement, Psychology; Smoking; Substance Withdrawal Syndrome; Time Factors	1995
Three methods of opioid detoxification in a primary care setting. A randomized trial. Annals of internal medicine, 1997, Oct-01, Volume: 127, Issue:7 Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Buprenorphine; Clonidine; Double-Blind Method; Drug Therapy, Combination; Female; Heroin; Heroin Dependence; Humans; Inactivation, Metabolic; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Primary Health Care; Substance Withdrawal Syndrome	1997
Efficacy and safety of two new methods of rapid intravenous detoxification in heroin addicts previously treated without success. The British journal of psychiatry : the journal of mental science, 1997, Volume: 171 Topics: Adult; Conscious Sedation; Critical Care; Heroin Dependence; Humans; Inactivation, Metabolic; Infusions, Intravenous; Length of Stay; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Recurrence; Substance Withdrawal Syndrome; Treatment Failure	1997
Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone. The Annals of pharmacotherapy, 1997, Volume: 31, Issue:11 Topics: Administration, Oral; Adult; Drug Compounding; Drug Stability; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Substance-Related Disorders	1997
Simultaneous increases in respiration and sympathetic function during opiate detoxification. Journal of neurosurgical anesthesiology, 1998, Volume: 10, Issue:4 Topics: Adult; Blood Pressure; Electroencephalography; Female; Heart Rate; Humans; Male; Naltrexone; Narcotic Antagonists; Narcotics; Pulmonary Ventilation; Substance Withdrawal Syndrome; Sympathetic Nervous System	1998
Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology, 1998, Volume: 140, Issue:2 Topics: Adult; Affect; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Nicotine; Reinforcement, Psychology; Smoking; Substance Withdrawal Syndrome	1998
Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure. Journal of toxicology. Clinical toxicology, 1999, Volume: 37, Issue:1 Topics: Acute Kidney Injury; Adult; Anesthesia; Codeine; Female; Heroin Dependence; Humans; Male; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Respiratory Insufficiency; Substance Withdrawal Syndrome; Thyroid Hormones	1999
Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology, 1999, Volume: 142, Issue:2 Topics: Adult; Analysis of Variance; Cues; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Nicotine; Smoking; Substance Withdrawal Syndrome	1999
Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology, 1999, Volume: 143, Issue:4 Topics: Adult; Affect; Analysis of Variance; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Placebos; Smoking; Substance Withdrawal Syndrome; Surveys and Questionnaires	1999
A pilot study of naltrexone-accelerated detoxification in opioid dependence. The Medical journal of Australia, 1999, Jul-05, Volume: 171, Issue:1 Topics: Adolescent; Adult; Analgesics; Anti-Anxiety Agents; Clonidine; Conscious Sedation; Female; Flunitrazepam; Heroin; Heroin Dependence; Hormones; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Octreotide; Pilot Projects; Substance Withdrawal Syndrome; Time Factors	1999
Naltrexone shortened opioid detoxification with buprenorphine. Drug and alcohol dependence, 1999, Oct-01, Volume: 56, Issue:3 Topics: Adult; Analgesics; Area Under Curve; Buprenorphine; Clonidine; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Heroin; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome	1999
Rapid opioid detoxification during general anesthesia: a review of 20 patients. Anesthesiology, 1999, Volume: 91, Issue:6 Topics: Adult; Anesthesia, General; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome	1999
Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA, 2000, Jan-19, Volume: 283, Issue:3 Topics: Adult; Analgesics, Opioid; Constipation; Double-Blind Method; Female; Gastrointestinal Transit; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Quaternary Ammonium Compounds; Statistics, Nonparametric; Substance Withdrawal Syndrome	2000
Rapid opiate detoxication in outpatient treatment: relationship with naltrexone compliance. Journal of substance abuse treatment, 2000, Volume: 18, Issue:2 Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Anti-Inflammatory Agents, Non-Steroidal; Baclofen; Clonidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; GABA Agents; Heroin Dependence; Humans; Inactivation, Metabolic; Ketoprofen; Male; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Oxazepam; Patient Compliance; Substance Withdrawal Syndrome; Treatment Outcome	2000
EEG controlled rapid opioid withdrawal under general anaesthesia. British journal of anaesthesia, 2000, Volume: 84, Issue:2 Topics: Anesthesia, General; Anesthetics, Intravenous; Electroencephalography; Female; Humans; Male; Monitoring, Physiologic; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Propofol; Substance Withdrawal Syndrome	2000
Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD). Journal of addictive diseases, 2000, Volume: 19, Issue:2 Topics: Adolescent; Adult; Aftercare; Anesthesia, General; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome and Process Assessment, Health Care; Recurrence; Retreatment; Substance Withdrawal Syndrome	2000
Combined use of trazodone-naltrexone versus clonidine-naltrexone in rapid withdrawal from methadone treatment. A comparative inpatient study. Drug and alcohol dependence, 2000, Jun-01, Volume: 59, Issue:3 Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Analysis of Variance; Clonidine; Drug Therapy, Combination; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Substance Withdrawal Syndrome; Trazodone	2000
Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification. Drug and alcohol dependence, 2000, May-01, Volume: 59, Issue:2 Topics: Adult; Blood Pressure; Clonidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Neurologic Examination; Opioid-Related Disorders; Substance Abuse Treatment Centers; Substance Withdrawal Syndrome	2000
Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacology, biochemistry, and behavior, 2000, Volume: 66, Issue:3 Topics: Adult; Affect; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder	2000
Plasma catecholamines during an ultrarapid heroin detoxification. Annals of the New York Academy of Sciences, 2000, Volume: 914 Topics: Adult; Analysis of Variance; Catecholamines; Drug Administration Routes; Drug Therapy, Combination; Female; Heroin; Heroin Dependence; Humans; Inactivation, Metabolic; Male; Naloxone; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Systole; Treatment Outcome	2000
Naltrexone's effects on reactivity to alcohol cues among alcoholic men. Journal of abnormal psychology, 2000, Volume: 109, Issue:4 Topics: Adult; Alcohol Drinking; Alcoholism; Arousal; Attention; Cues; Humans; Male; Middle Aged; Motivation; Naltrexone; Substance Withdrawal Syndrome; Taste	2000
24-Hour opiate detoxification and antagonist induction at home--the 'Asturian method': a report on 1368 procedures. Addiction biology, 2002, Volume: 7, Issue:2 Topics: Administration, Oral; Adult; Aftercare; Anti-Anxiety Agents; Benzodiazepines; Clonidine; Drug Implants; Female; Follow-Up Studies; Heroin Dependence; Home Care Services, Hospital-Based; Humans; Male; Methadone; Naltrexone; Octreotide; Opioid-Related Disorders; Patient Admission; Substance Withdrawal Syndrome; Time Factors	2002
Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone. NIDA research monograph, 1992, Volume: 121 Topics: Adult; Blood Pressure; Buprenorphine; Double-Blind Method; Female; Humans; Male; Methadone; Methoxyhydroxyphenylglycol; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	1992
Treatment of heroin addicts using buprenorphine. The American journal of drug and alcohol abuse, 1991, Volume: 17, Issue:2 Topics: Adult; Buprenorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Neurologic Examination; Substance Withdrawal Syndrome	1991
Opioid antagonist challenges in buprenorphine maintained patients. Drug and alcohol dependence, 1990, Volume: 25, Issue:1 Topics: Administration, Sublingual; Adult; Buprenorphine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Infusions, Intravenous; Male; Methadone; Naloxone; Naltrexone; Substance Withdrawal Syndrome	1990
Rapid detoxification from opioid dependence. The American journal of psychiatry, 1989, Volume: 146, Issue:10 Topics: Buprenorphine; Clinical Trials as Topic; Double-Blind Method; Humans; Naloxone; Naltrexone; Opioid-Related Disorders; Placebos; Substance Withdrawal Syndrome	1989
Opioid peptides and primary biliary cirrhosis. BMJ (Clinical research ed.), 1988, Dec-10, Volume: 297, Issue:6662 Topics: Adult; Aged; Bilirubin; Fatigue; Female; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pruritus; Substance Withdrawal Syndrome	1988
Clonidine treatment of the opiate withdrawal syndrome. A review of clinical trials of a theory. Acta psychiatrica Scandinavica. Supplementum, 1986, Volume: 327 Topics: Adrenergic Fibers; Animals; Antidepressive Agents, Tricyclic; Brain; Clinical Trials as Topic; Clonidine; Dextropropoxyphene; Drug Therapy, Combination; Heroin Dependence; Humans; Locus Coeruleus; Methadone; Morphine; Naltrexone; Narcotics; Norepinephrine; Rats; Substance Withdrawal Syndrome	1986

Other Studies

325 other study(ies) available for naltrexone and Drug Withdrawal Symptoms

Article	Year
Analgesic narcotic antagonists. 9. 6-Methylene-8 beta-alkyl-N-(cycloalkylmethyl)-3-hydroxy- or -methoxymorphinans. Journal of medicinal chemistry, 1981, Volume: 24, Issue:12 Topics: Analgesics; Animals; Chemical Phenomena; Chemistry; Haplorhini; Humans; Mice; Morphinans; Morphine Dependence; Narcotic Antagonists; Rats; Reaction Time; Substance Withdrawal Syndrome	1981
Severe opioid withdrawal precipitated by Vivitrol®. The American journal of emergency medicine, 2018, Volume: 36, Issue:6 Topics: Adult; Emergency Medical Services; Female; Heroin Dependence; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome	2018
Managing unplanned severe opiate withdrawal after Vivitrol. The American journal of emergency medicine, 2019, Volume: 37, Issue:2 Topics: Humans; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	2019
Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials. Drug and alcohol dependence, 2022, 04-01, Volume: 233 Topics: Analgesics, Opioid; Delayed-Action Preparations; Heroin; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome	2022
Olanzapine/samidorphan precipitated opioid withdrawal in a patient taking transdermal fentanyl. Clinical toxicology (Philadelphia, Pa.), 2022, Volume: 60, Issue:7 Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Naltrexone; Olanzapine; Substance Withdrawal Syndrome	2022
Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis. Internal medicine (Tokyo, Japan), 2020, Jan-15, Volume: 59, Issue:2 Topics: Analgesics, Opioid; Breast Neoplasms; Cancer Pain; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Induced Constipation; Oxycodone; Substance Withdrawal Syndrome	2020
Discrimination learning in oxycodone-treated nonhuman primates. Drug and alcohol dependence, 2020, 02-01, Volume: 207 Topics: Analgesics, Opioid; Animals; Discrimination Learning; Dose-Response Relationship, Drug; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Primates; Saimiri; Self Administration; Substance Withdrawal Syndrome	2020
A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. The American journal of drug and alcohol abuse, 2020, 05-03, Volume: 46, Issue:3 Topics: Adult; Buprenorphine; Delayed-Action Preparations; Feasibility Studies; Female; Heroin Dependence; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Recurrence; Substance Withdrawal Syndrome; Young Adult	2020
Mu-opioid antagonism in the treatment of cannabis use disorder Journal of psychiatry & neuroscience : JPN, 2020, 03-01, Volume: 45, Issue:2 Topics: Craving; Dose-Response Relationship, Drug; Humans; Male; Marijuana Abuse; Middle Aged; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Recurrence; Substance Withdrawal Syndrome	2020
Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis. Addiction (Abingdon, England), 2020, Volume: 115, Issue:8 Topics: Adolescent; Adult; Buprenorphine; Cohort Studies; Drug Overdose; Female; Humans; Male; Massachusetts; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Residential Treatment; Retrospective Studies; Substance Withdrawal Syndrome; Young Adult	2020
Naloxone-Induced Acute Opioid Withdrawal in a Stabilized Extended-Release Naltrexone-Treated Patient. The primary care companion for CNS disorders, 2020, Sep-17, Volume: 22, Issue:5 Topics: Analgesics, Opioid; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome	2020
Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report. Harm reduction journal, 2020, 10-07, Volume: 17, Issue:1 Topics: Adult; Analgesics, Opioid; Buprenorphine; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome	2020
Tobacco withdrawal increases junk food intake: The role of the endogenous opioid system. Drug and alcohol dependence, 2021, 08-01, Volume: 225 Topics: Analgesics, Opioid; Eating; Humans; Naltrexone; Nicotiana; Nicotine; Substance Withdrawal Syndrome	2021
Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine. Fundamental & clinical pharmacology, 2017, Volume: 31, Issue:5 Topics: Adult; Aged; Alcoholism; Analgesics, Opioid; Female; France; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Pancreatitis; Retrospective Studies; Substance Withdrawal Syndrome	2017
Current Progress in Opioid Treatment. The American journal of psychiatry, 2017, 05-01, Volume: 174, Issue:5 Topics: Buprenorphine; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome	2017
Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. Journal of substance abuse treatment, 2018, Volume: 85 Topics: Adult; Female; Humans; Injections, Intramuscular; Inpatients; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Randomized Controlled Trials as Topic; Recurrence; Substance Withdrawal Syndrome	2018
A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment. The American journal of drug and alcohol abuse, 2018, Volume: 44, Issue:3 Topics: Adult; Amines; Analgesics, Opioid; Buprenorphine; Clonidine; Counseling; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxyzine; Male; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult	2018
Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat It With… More Buprenorphine. Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:5 Topics: Alcoholism; Antisocial Personality Disorder; Buprenorphine; Heroin Dependence; Humans; Male; Medication Errors; Middle Aged; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome	2017
Opioid system contribution to the antidepressant-like action of m-trifluoromethyl-diphenyl diselenide in mice: A compound devoid of tolerance and withdrawal syndrome. Journal of psychopharmacology (Oxford, England), 2017, Volume: 31, Issue:9 Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Male; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Organosilicon Compounds; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Swimming	2017
Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6- Pharmacology research & perspectives, 2018, Volume: 6, Issue:4 Topics: Analgesics, Opioid; Animals; Conditioning, Operant; Discrimination Learning; Drug Tolerance; Male; Morphine Derivatives; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu; Substance Withdrawal Syndrome	2018
Mu Opioid Receptor Agonist DAMGO Produces Place Conditioning, Abstinence-induced Withdrawal, and Naltrexone-Dependent Locomotor Activation in Planarians. Neuroscience, 2018, 08-21, Volume: 386 Topics: Analgesics, Opioid; Animals; Conditioning, Psychological; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Locomotion; Naltrexone; Narcotic Antagonists; Planarians; Receptors, Opioid, mu; Substance Withdrawal Syndrome	2018
Maladaptive behavioral regulation in alcohol dependence: Role of kappa-opioid receptors in the bed nucleus of the stria terminalis. Neuropharmacology, 2018, 09-15, Volume: 140 Topics: Alcoholism; Animals; Conditioning, Operant; Dynorphins; Ethanol; Gene Expression Regulation; Male; Maze Learning; Naltrexone; Rats; Receptors, Opioid, kappa; RNA, Messenger; Self Administration; Septal Nuclei; Substance Withdrawal Syndrome; Up-Regulation; Vocalization, Animal	2018
Extended-release morphine sulfate and naltrexone hydrochloride (EMBEDA): naltrexone-associated withdrawal and abuse-related effects in patients with chronic pain and recreational opioid users. Current medical research and opinion, 2019, Volume: 35, Issue:3 Topics: Adult; Chronic Pain; Delayed-Action Preparations; Drug Combinations; Female; Humans; Male; Middle Aged; Morphine; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	2019
Exploring Sex Differences in the Attenuation of Ethanol Drinking by Naltrexone in Dependent Rats During Early and Protracted Abstinence. Alcoholism, clinical and experimental research, 2018, Volume: 42, Issue:12 Topics: Administration, Inhalation; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Animals; Ethanol; Female; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Self Administration; Sex Characteristics; Substance Withdrawal Syndrome	2018
Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report. Substance abuse, 2019, Volume: 40, Issue:2 Topics: Adult; Antidiarrheals; Antiemetics; Antipruritics; Buprenorphine; Clonidine; Deprescriptions; Drug Substitution; Female; Humans; Loperamide; Methadone; Methocarbamol; Muscle Relaxants, Central; Naltrexone; Narcotic Antagonists; Ondansetron; Opiate Substitution Treatment; Opioid-Related Disorders; Promethazine; Substance Withdrawal Syndrome; Sympatholytics	2019
Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2019, Volume: 44, Issue:10 Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Animals; Behavior, Animal; Choice Behavior; Clonidine; Drug-Seeking Behavior; Feeding Behavior; Female; Fentanyl; Food; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats; Reinforcement, Psychology; Self Administration; Substance Withdrawal Syndrome; Tetanus Toxoid; Vaccines, Conjugate	2019
The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity. Naunyn-Schmiedeberg's archives of pharmacology, 2013, Volume: 386, Issue:6 Topics: Administration, Oral; Analgesics, Opioid; Animals; Benzamides; Central Nervous System; Dogs; Female; Gastrointestinal Tract; Male; Mice; Morphine; Naltrexone; Narcotic Antagonists; Pain; Piperidines; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Tropanes	2013
Withdrawal syndrome caused by naltrexone in opioid abusers. Human & experimental toxicology, 2014, Volume: 33, Issue:6 Topics: Adolescent; Adult; Aged; Cross-Sectional Studies; Female; Humans; Iran; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk Factors; Severity of Illness Index; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Young Adult	2014
Protracted withdrawal from ethanol and enhanced responsiveness stress: regulation via the dynorphin/kappa opioid receptor system. Alcohol (Fayetteville, N.Y.), 2013, Volume: 47, Issue:5 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Alcoholism; Analgesics, Non-Narcotic; Animals; Anxiety; Dose-Response Relationship, Drug; Dynorphins; Ethanol; Male; Maze Learning; Motor Activity; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, kappa; Stress, Psychological; Substance Withdrawal Syndrome	2013
Constitutive μ-opioid receptor activity leads to long-term endogenous analgesia and dependence. Science (New York, N.Y.), 2013, Sep-20, Volume: 341, Issue:6152 Topics: Acute Pain; Adenosine Monophosphate; Adenylyl Cyclases; Animals; Chronic Pain; Disease Models, Animal; Freund's Adjuvant; Hyperalgesia; Isoflurane; Male; Mice; Naltrexone; Nociceptive Pain; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid, mu; Spinal Cord; Substance Withdrawal Syndrome	2013
Long-term antagonism of κ opioid receptors prevents escalation of and increased motivation for heroin intake. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013, Dec-04, Volume: 33, Issue:49 Topics: Animals; Anxiety; Catheterization; Conditioning, Operant; Enkephalins; Heroin Dependence; Immunohistochemistry; Male; Motivation; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Protein Precursors; Rats; Rats, Wistar; Receptors, Opioid, kappa; Reinforcement Schedule; Self Administration; Substance Withdrawal Syndrome	2013
Long-term relapse of ultra-rapid opioid detoxification. Journal of addictive diseases, 2014, Volume: 33, Issue:1 Topics: Adolescent; Adult; Anesthesia, General; Employment; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prospective Studies; Recurrence; Regression Analysis; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult	2014
Use of naltrexone in ketamine dependence. Addictive behaviors, 2014, Volume: 39, Issue:8 Topics: Adult; Craving; Humans; Ketamine; Male; Naltrexone; Narcotic Antagonists; Substance Abuse, Intravenous; Substance Withdrawal Syndrome; Treatment Outcome	2014
Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the rat. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014, Volume: 39, Issue:11 Topics: Acenaphthenes; Alcohol Deterrents; Alcohol Drinking; Animals; Benzimidazoles; Choice Behavior; Dose-Response Relationship, Drug; Drug-Seeking Behavior; HEK293 Cells; Humans; Male; Naltrexone; Narcotic Antagonists; Nociceptin; Nociceptin Receptor; Opioid Peptides; Rats; Rats, Wistar; Receptors, Opioid; Stress, Psychological; Substance Withdrawal Syndrome	2014
Effect of naltrexone on neuropathic pain in mice locally transfected with the mutant μ-opioid receptor gene in spinal cord. British journal of pharmacology, 2015, Volume: 172, Issue:2 Topics: Analgesics; Animals; Conditioning, Psychological; Genetic Vectors; HEK293 Cells; Humans; Lentivirus; Male; Mice, Inbred C57BL; Morphine; Mutation; Naltrexone; Narcotic Antagonists; Neuralgia; Receptors, Opioid, mu; Reward; Spinal Cord; Spinal Nerves; Substance Withdrawal Syndrome; Transfection	2015
Hypothalamic-pituitary-adrenal axis response to oral naltrexone in alcoholics during early withdrawal. Pharmacopsychiatry, 2014, Volume: 47, Issue:4-5 Topics: Administration, Oral; Adrenocorticotropic Hormone; Adult; Diazepam; Ethanol; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Naltrexone; Pituitary-Adrenal System; Substance Withdrawal Syndrome	2014
Narcotic-induced pain. The American journal of medicine, 2015, Volume: 128, Issue:4 Topics: Abdominal Pain; Adult; Analgesics, Opioid; Anorexia; Chronic Disease; Diabetes Mellitus, Type 1; Drug Administration Schedule; Endoscopy, Gastrointestinal; Gastroparesis; Humans; Hypertension; Kidney Failure, Chronic; Male; Naltrexone; Narcotic Antagonists; Nausea; Neuralgia; Quaternary Ammonium Compounds; Substance Withdrawal Syndrome; Treatment Outcome; Vomiting	2015
The kappa-opioid receptor antagonist, nor-binaltorphimine (nor-BNI), decreases morphine withdrawal and the consequent conditioned place aversion in rats. Behavioural brain research, 2015, Apr-15, Volume: 283 Topics: Animals; Conditioning, Psychological; Defecation; Dynorphins; Male; Morphine; Morphine Dependence; Motor Activity; Naltrexone; Narcotic Antagonists; Narcotics; Neurotransmitter Agents; Random Allocation; Rats, Long-Evans; Receptors, Opioid, kappa; Spatial Behavior; Substance Withdrawal Syndrome	2015
Enkephalin analog, cyclo[N(ε),N(β)-carbonyl-D-Lys(2),Dap(5)] enkephalinamide (cUENK6), inhibits the ethanol withdrawal-induced anxiety-like behavior in rats. Alcohol (Fayetteville, N.Y.), 2015, Volume: 49, Issue:3 Topics: Analgesics, Opioid; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Central Nervous System Depressants; Enkephalin, Leucine; Enkephalins; Ethanol; Morphine; Naltrexone; Narcotic Antagonists; Neurotransmitter Agents; Rats; Rats, Wistar; Receptors, Opioid, delta; Receptors, Opioid, mu; Substance Withdrawal Syndrome	2015
Antagonism of κ opioid receptor in the nucleus accumbens prevents the depressive-like behaviors following prolonged morphine abstinence. Behavioural brain research, 2015, Sep-15, Volume: 291 Topics: Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Dose-Response Relationship, Drug; Enkephalins; Male; Mice, Inbred C57BL; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Narcotics; Nucleus Accumbens; Protein Precursors; Receptors, Opioid, kappa; RNA, Messenger; Substance Withdrawal Syndrome	2015
Severe opioid withdrawal syndrome after a single dose of nalmefene. European journal of clinical pharmacology, 2015, Volume: 71, Issue:8 Topics: Adult; Alcoholism; Analgesics, Opioid; Codeine; Contraindications; Drug Interactions; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome	2015
Dissociating Motivational From Physiological Withdrawal in Alcohol Dependence: Role of Central Amygdala κ-Opioid Receptors. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2016, Volume: 41, Issue:2 Topics: Administration, Intranasal; Alcoholism; Animals; Central Amygdaloid Nucleus; Central Nervous System Depressants; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats, Wistar; Receptors, Opioid, kappa; Self Administration; Substance Withdrawal Syndrome	2016
Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals. Alcoholism, clinical and experimental research, 2015, Volume: 39, Issue:9 Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals; Drug Therapy, Combination; Male; Naltrexone; Narcotic Antagonists; Prazosin; Rats; Substance Withdrawal Syndrome; Treatment Outcome	2015
Withdrawal syndrome after co-medication of opioid maintenance therapy with nalmefene: unrecognized interaction. European journal of clinical pharmacology, 2015, Volume: 71, Issue:12 Topics: Analgesics, Opioid; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome	2015
[Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions]. Praxis, 2015, Oct-14, Volume: 104, Issue:21 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Alcoholism; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Pharmacovigilance; Substance Withdrawal Syndrome	2015
Alterations of naltrexone-induced conditioned place avoidance by pre-exposure to high fructose corn syrup or heroin in Sprague-Dawley rats. Psychopharmacology, 2016, Volume: 233, Issue:3 Topics: Animals; Avoidance Learning; Conditioning, Operant; Dose-Response Relationship, Drug; Food Deprivation; Heroin; High Fructose Corn Syrup; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome	2016
Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting. Journal of clinical psychopharmacology, 2016, Volume: 36, Issue:1 Topics: Adult; Alcohol Drinking; Analgesics, Opioid; Buprenorphine; Drug Interactions; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome	2016
Short-term UROD treatment on cerebral function in codeine-containing cough syrups dependent male individuals. European radiology, 2016, Volume: 26, Issue:9 Topics: Adult; Anesthesia, General; Antitussive Agents; Brain; Brain Mapping; Codeine; Humans; Magnetic Resonance Imaging; Male; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prospective Studies; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult	2016
Combination of Levo-Tetrahydropalmatine and Low Dose Naltrexone: A Promising Treatment for Prevention of Cocaine Relapse. The Journal of pharmacology and experimental therapeutics, 2016, Volume: 357, Issue:2 Topics: Animals; Berberine Alkaloids; beta-Endorphin; Cocaine-Related Disorders; Drug Therapy, Combination; Drug-Seeking Behavior; Hypothalamus; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Pro-Opiomelanocortin; Rats; Rats, Wistar; Recurrence; Self Administration; Substance Withdrawal Syndrome	2016
Preferential Delivery of an Opioid Antagonist to the Fetal Brain in Pregnant Mice. The Journal of pharmacology and experimental therapeutics, 2016, Volume: 358, Issue:1 Topics: Animals; Behavior, Animal; Brain; Dose-Response Relationship, Drug; Female; Mice, Inbred C57BL; Morphine; Naltrexone; Narcotic Antagonists; Placenta; Pregnancy; Substance Withdrawal Syndrome; Tissue Distribution	2016
Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification. Journal of substance abuse treatment, 2016, Volume: 66 Topics: Adult; Buprenorphine; Delayed-Action Preparations; Female; Humans; Interviews as Topic; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Preference; Substance Withdrawal Syndrome; Young Adult	2016
Involvement of delta opioid receptors in alcohol withdrawal-induced mechanical allodynia in male C57BL/6 mice. Drug and alcohol dependence, 2016, Oct-01, Volume: 167 Topics: Analgesics; Analgesics, Opioid; Animals; Ethanol; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Naltrexone; Narcotic Antagonists; Pain Management; Quinolines; Receptors, Opioid, delta; Receptors, Opioid, mu; Substance Withdrawal Syndrome	2016
Correspondence of Interactive Voice Response (IVR) reports of nicotine withdrawal, craving, and negative mood with questionnaire ratings. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2008, Volume: 10, Issue:6 Topics: Adult; Comorbidity; Depression; Female; Humans; Irritable Mood; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Self Disclosure; Self-Assessment; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires	2008
Some effects of dopamine transporter and receptor ligands on discriminative stimulus, physiologic, and directly observable indices of opioid withdrawal in rhesus monkeys. Psychopharmacology, 2009, Volume: 203, Issue:2 Topics: Analgesics, Opioid; Animals; Behavior, Animal; Discrimination, Psychological; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Female; Ligands; Macaca mulatta; Male; Naltrexone; Narcotic Antagonists; Receptors, Dopamine; Substance Withdrawal Syndrome	2009
[Pharmacotherapy of alcohol dependence]. MMW Fortschritte der Medizin, 2008, May-19, Volume: 150 Suppl 2 Topics: Acamprosate; Adrenergic beta-Antagonists; Alcohol Deterrents; Alcoholism; Ambulatory Care; Anticonvulsants; Benzodiazepines; Chlormethiazole; Ethanol; Family Practice; Humans; Naltrexone; Patient Admission; Secondary Prevention; Substance Withdrawal Syndrome; Taurine	2008
Antagonist-precipitated and discontinuation-induced withdrawal in morphine-dependent rhesus monkeys. Psychopharmacology, 2008, Volume: 201, Issue:3 Topics: Animals; Behavior, Animal; Body Temperature; Circadian Rhythm; Conditioning, Operant; Discrimination Learning; Drug Administration Schedule; Female; Heart Rate; Humans; Injections, Subcutaneous; Macaca mulatta; Morphine; Morphine Dependence; Motor Activity; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Sodium Chloride; Stereotyped Behavior; Substance Withdrawal Syndrome; Time Factors	2008
Narp regulates long-term aversive effects of morphine withdrawal. Behavioral neuroscience, 2008, Volume: 122, Issue:4 Topics: Amygdala; Animals; Avoidance Learning; Behavior, Animal; C-Reactive Protein; Conditioning, Operant; Disease Models, Animal; Extinction, Psychological; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Nerve Tissue Proteins; Retention, Psychology; Septal Nuclei; Substance Withdrawal Syndrome	2008
Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction (Abingdon, England), 2008, Volume: 103, Issue:8 Topics: Adolescent; Analgesics, Opioid; Delayed-Action Preparations; Female; Heroin Dependence; Humans; Metabolic Clearance Rate; Naltrexone; Narcotic Antagonists; Oxycodone; Patient Acceptance of Health Care; Substance Withdrawal Syndrome	2008
Unplanned admissions to two Sydney public hospitals after naltrexone implants. The Medical journal of Australia, 2008, Oct-20, Volume: 189, Issue:8 Topics: Causality; Drug Implants; Heroin Dependence; Hospitals, Public; Humans; Naltrexone; Narcotic Antagonists; New South Wales; Substance Withdrawal Syndrome	2008
Unplanned admissions to two Sydney public hospitals after naltrexone implants. The Medical journal of Australia, 2008, Oct-20, Volume: 189, Issue:8 Topics: Drug Implants; Heroin Dependence; Hospitals, Public; Humans; Naltrexone; Narcotic Antagonists; Research Design; Substance Withdrawal Syndrome	2008
Unplanned admissions to two Sydney public hospitals after naltrexone implants. The Medical journal of Australia, 2008, Oct-20, Volume: 189, Issue:8 Topics: Heroin Dependence; Hospitals, Public; Humans; Inactivation, Metabolic; Naltrexone; Narcotic Antagonists; Research Design; Substance Withdrawal Syndrome	2008
Unplanned admissions to two Sydney public hospitals after naltrexone implants. The Medical journal of Australia, 2008, Oct-20, Volume: 189, Issue:8 Topics: Drug Implants; Gastrointestinal Agents; Heroin Dependence; Hospitals, Public; Humans; Naltrexone; Narcotic Antagonists; New South Wales; Octreotide; Substance Withdrawal Syndrome	2008
Effects of training and withdrawal periods on heroin seeking induced by conditioned cue in an animal of model of relapse. Psychopharmacology, 2009, Volume: 203, Issue:4 Topics: Animals; Behavior, Addictive; Behavior, Animal; Conditioning, Operant; Cues; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Exploratory Behavior; Heroin; Heroin Dependence; Male; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Secondary Prevention; Self Administration; Substance Withdrawal Syndrome	2009
Mu-opioid receptor redistribution in the locus coeruleus upon precipitation of withdrawal in opiate-dependent rats. Anatomical record (Hoboken, N.J. : 2007), 2009, Volume: 292, Issue:3 Topics: Analgesics, Opioid; Animals; Fluorescent Antibody Technique; Immunoenzyme Techniques; Locus Coeruleus; Male; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Substance Withdrawal Syndrome	2009
The unconditioned fear produced by morphine withdrawal is regulated by mu- and kappa-opioid receptors in the midbrain tectum. Behavioural brain research, 2009, Dec-01, Volume: 204, Issue:1 Topics: Analgesics, Opioid; Animals; Catheterization; Dose-Response Relationship, Drug; Electric Stimulation; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Escape Reaction; Fear; Freezing Reaction, Cataleptic; Male; Microinjections; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, kappa; Receptors, Opioid, mu; Substance Withdrawal Syndrome; Tectum Mesencephali	2009
Withania somnifera prevents morphine withdrawal-induced decrease in spine density in nucleus accumbens shell of rats: a confocal laser scanning microscopy study. Neurotoxicity research, 2009, Volume: 16, Issue:4 Topics: Analysis of Variance; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Dendritic Spines; Disease Models, Animal; Male; Microscopy, Confocal; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Neurons; Nucleus Accumbens; Phytotherapy; Plant Extracts; Rats; Rats, Sprague-Dawley; Silver Staining; Substance Withdrawal Syndrome; Time Factors; Withania	2009
Prodynorphin gene deficiency potentiates nalbuphine-induced behavioral sensitization and withdrawal syndrome in mice. Drug and alcohol dependence, 2009, Sep-01, Volume: 104, Issue:1-2 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Area Under Curve; Blotting, Western; Dopamine; Enkephalins; Gene Expression; Genes, fos; Mice; Mice, Knockout; Microdialysis; Motor Activity; Nalbuphine; Naloxone; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Protein Precursors; Receptors, Opioid, kappa; Reverse Transcriptase Polymerase Chain Reaction; Substance Withdrawal Syndrome	2009
Regional Fos expression induced by morphine withdrawal in the 7-day-old rat. Developmental psychobiology, 2009, Volume: 51, Issue:7 Topics: Analysis of Variance; Animals; Animals, Newborn; Cell Count; Female; Immunohistochemistry; Locus Coeruleus; Male; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Narcotics; Nucleus Accumbens; Periaqueductal Gray; Pregnancy; Proto-Oncogene Proteins c-fos; Rats; Rats, Long-Evans; Spinal Cord; Substance Withdrawal Syndrome	2009
Possible involvement of the hypothalamic pro-opiomelanocortin gene and beta-endorphin expression on acute morphine withdrawal development. Brain research bulletin, 2009, Dec-16, Volume: 80, Issue:6 Topics: Animals; Arcuate Nucleus of Hypothalamus; Baclofen; beta-Endorphin; Dose-Response Relationship, Drug; GABA Agonists; Gene Expression; Hypothalamus; Male; Mice; Mice, Inbred ICR; Morphine; Muscimol; Naltrexone; Narcotic Antagonists; Narcotics; Pro-Opiomelanocortin; Substance Withdrawal Syndrome	2009
[Preventing weight gain in smoking cessation: there is no miracle solution]. Revue medicale suisse, 2009, Aug-05, Volume: 5, Issue:212 Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Fluoxetine; Humans; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Risk; Selective Serotonin Reuptake Inhibitors; Smoking Cessation; Substance Withdrawal Syndrome; Weight Gain	2009
Ultra-rapid opiate detoxification followed by nine months of naltrexone maintenance therapy in Iran. Pharmacopsychiatry, 2010, Volume: 43, Issue:4 Topics: Adult; Anesthesia, General; Follow-Up Studies; Humans; Iran; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies; Severity of Illness Index; Substance Withdrawal Syndrome; Young Adult	2010
In vivo characterization of the opioid antagonist nalmefene in mice. Life sciences, 2010, Apr-10, Volume: 86, Issue:15-16 Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Inhibitory Concentration 50; Male; Mice; Mice, Inbred ICR; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Pain; Substance Withdrawal Syndrome; Time Factors	2010
Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda). Annals of emergency medicine, 2010, Volume: 55, Issue:3 Topics: Adult; Drug Combinations; Female; Humans; Morphine; Naltrexone; Patient Education as Topic; Substance Withdrawal Syndrome	2010
Naltrexone attenuates amphetamine-induced locomotor sensitization in the rat. Addiction biology, 2011, Volume: 16, Issue:1 Topics: Amphetamine-Related Disorders; Animals; Association Learning; Brain; Central Nervous System Stimulants; Conditioning, Classical; Cues; Dextroamphetamine; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Premedication; Rats; Receptors, Opioid; Substance Withdrawal Syndrome	2011
First case of stress cardiomyopathy as a result of methadone withdrawal secondary to drug-drug interaction. The American journal of emergency medicine, 2010, Volume: 28, Issue:3 Topics: Adult; Drug Interactions; Echocardiography; Electrocardiography; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Substance Withdrawal Syndrome; Takotsubo Cardiomyopathy	2010
Systemic κ-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats. Addiction biology, 2011, Volume: 16, Issue:1 Topics: Administration, Inhalation; Alcohol Deterrents; Alcoholism; Animals; Dose-Response Relationship, Drug; Dynorphins; Ethanol; Injections, Subcutaneous; Male; Naltrexone; Narcotic Antagonists; Premedication; Rats; Rats, Wistar; Receptors, Opioid, kappa; Self Administration; Substance Withdrawal Syndrome	2011
Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety. The Journal of pharmacology and experimental therapeutics, 2010, Volume: 335, Issue:1 Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Benzamides; Diazepam; Ligands; Mice; Mice, Inbred C57BL; Mice, Knockout; Naltrexone; Narcotic Antagonists; Piperazines; Quinolines; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Opioid, delta; Substance Withdrawal Syndrome	2010
Effect of ultra-rapid opiate detoxification on withdrawal syndrome. Journal of addictive diseases, 2010, Volume: 29, Issue:4 Topics: Adult; Anesthesia, General; Female; Humans; Male; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome	2010
Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal. The Journal of pharmacology and experimental therapeutics, 2011, Volume: 336, Issue:2 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Buprenorphine; Dose-Response Relationship, Drug; Drug Tolerance; Female; Levorphanol; Macaca mulatta; Male; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome	2011
Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts. Journal of substance abuse treatment, 2011, Volume: 41, Issue:3 Topics: Adult; Alcohol Drinking; Alcoholism; Automobile Driving; Criminal Law; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Michigan; Missouri; Naltrexone; Narcotic Antagonists; Pilot Projects; Retrospective Studies; Substance Abuse Detection; Substance Withdrawal Syndrome; Temperance	2011
Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments. British journal of pharmacology, 2012, Volume: 165, Issue:2 Topics: Adamantane; Analgesics, Opioid; Animals; Behavior, Animal; Conditioning, Classical; Dipeptides; Drug Tolerance; Fentanyl; Hot Temperature; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain; Receptors, Neuropeptide; Substance Withdrawal Syndrome	2012
Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology, 2012, Volume: 62, Issue:1 Topics: Analysis of Variance; Animals; Cocaine; Conditioning, Operant; Depression; Disease Models, Animal; Dopamine Uptake Inhibitors; Drug Administration Routes; Immobility Response, Tonic; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Opioid, kappa; Reinforcement Schedule; Self Administration; Substance Withdrawal Syndrome; Swimming; Time Factors	2012
The role of opioid antagonist efficacy and constitutive opioid receptor activity in the opioid withdrawal syndrome in mice. Pharmacology, biochemistry, and behavior, 2011, Volume: 99, Issue:4 Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Male; Mice; Morphine Dependence; Naltrexone; Narcotic Antagonists; Narcotics; Receptors, Opioid; Substance Withdrawal Syndrome	2011
κ opioid regulation of anxiety-like behavior during acute ethanol withdrawal. Pharmacology, biochemistry, and behavior, 2012, Volume: 102, Issue:1 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Alcoholism; Animals; Anxiety; Behavior, Animal; Ethanol; Male; Naltrexone; Rats; Rats, Wistar; Receptors, Opioid, kappa; Substance Withdrawal Syndrome	2012
A 'miracle cure' misunderstood. Addiction (Abingdon, England), 2012, Volume: 107, Issue:8 Topics: Administration, Oral; Drug Implants; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome	2012
Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner. Psychopharmacology, 2012, Volume: 224, Issue:2 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Aging; Animals; Behavior, Animal; Dopamine; Dose-Response Relationship, Drug; Male; Naltrexone; Nicotine; Nucleus Accumbens; Rats; Rats, Wistar; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Tobacco Use Disorder	2012
Pharmacotherapy for adolescent alcohol use disorder. CNS drugs, 2012, Jul-01, Volume: 26, Issue:7 Topics: Acamprosate; Adolescent; Alcohol-Related Disorders; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Central Nervous System Stimulants; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Disulfiram; Humans; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders; Taurine	2012
Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists. ACS chemical neuroscience, 2011, Jul-20, Volume: 2, Issue:7 Topics: Animals; Caco-2 Cells; CHO Cells; Cricetinae; Cricetulus; Drug Implants; Guanosine 5'-O-(3-Thiotriphosphate); Heterocyclic Compounds; Humans; Male; Membranes; Mice; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Receptors, Opioid, mu; Substance Withdrawal Syndrome; Thalamus	2011
The monoamine stabilizer (-)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens. Biological psychiatry, 2012, Nov-15, Volume: 72, Issue:10 Topics: Alcohol Drinking; Animals; Behavioral Symptoms; Cues; Disease Models, Animal; Dopamine; Drug Discovery; Ethanol; Male; Microdialysis; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Piperidines; Rats; Reward; Secondary Prevention; Substance Withdrawal Syndrome	2012
A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence. Science translational medicine, 2012, Aug-08, Volume: 4, Issue:146 Topics: Animals; Buprenorphine; Cocaine; Cocaine-Related Disorders; Male; Naloxone; Naltrexone; Rats; Rats, Wistar; Substance Withdrawal Syndrome	2012
Opioid dependence. American family physician, 2012, Sep-15, Volume: 86, Issue:6 Topics: Buprenorphine; Clonidine; Evidence-Based Medicine; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Prognosis; Risk Factors; Substance Withdrawal Syndrome; Time Factors	2012
Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Dec-05, Volume: 32, Issue:49 Topics: Animals; Avoidance Learning; Brain; Cocaine; Corpus Striatum; Dopamine; Dynorphins; G-Protein-Coupled Receptor Kinase 3; Male; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microinjections; Naltrexone; Narcotic Antagonists; Nicotine; Nucleus Accumbens; p38 Mitogen-Activated Protein Kinases; Raphe Nuclei; Receptors, Opioid, kappa; Reward; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction; Stress, Psychological; Substance Withdrawal Syndrome; Synaptosomes	2012
Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects. Addiction biology, 2014, Volume: 19, Issue:4 Topics: Adult; Alcoholism; Brain; Brain Mapping; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Positron-Emission Tomography; Receptors, Opioid, mu; Severity of Illness Index; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Tobacco Use Disorder	2014
Double trouble-pregnancy and antagonist treatment in opioid dependence; two contentious issues needing further consideration and research. Addiction (Abingdon, England), 2013, Volume: 108, Issue:2 Topics: Buprenorphine; Female; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Randomized Controlled Trials as Topic; Research Design; Substance Withdrawal Syndrome	2013
Focal kappa-opioid receptor-mediated dependence and withdrawal in the nucleus paragigantocellularis. Pharmacology, biochemistry, and behavior, 2002, Volume: 74, Issue:1 Topics: Animals; Basal Ganglia; Butorphanol; Diffusion; Electric Stimulation; Male; Microinjections; Morphine; Morphine Dependence; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Stereotaxic Techniques; Stereotyped Behavior; Substance Withdrawal Syndrome	2002
Changes in urination/defecation, auditory startle response, and startle-induced ultrasonic vocalizations in rats undergoing morphine withdrawal: similarities and differences between acute and chronic dependence. The Journal of pharmacology and experimental therapeutics, 2003, Volume: 304, Issue:2 Topics: Acoustic Stimulation; Animals; Defecation; Male; Morphine Dependence; Naltrexone; Rats; Rats, Sprague-Dawley; Reflex, Startle; Substance Withdrawal Syndrome; Ultrasonics; Urination; Vocalization, Animal	2003
Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence. The Journal of pharmacology and experimental therapeutics, 2003, Volume: 304, Issue:3 Topics: Acute Disease; Analgesics, Opioid; Animals; Disease Models, Animal; Fentanyl; Male; Methadone; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Substance-Related Disorders	2003
Ultra-rapid opiate detoxification using deep sedation and prior oral buprenorphine preparation: long-term results. Drug and alcohol dependence, 2003, Apr-01, Volume: 69, Issue:3 Topics: Adult; Buprenorphine; Conscious Sedation; Family Practice; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Outcome and Process Assessment, Health Care; Premedication; Recurrence; Substance Withdrawal Syndrome; Time Factors; Vomiting	2003
Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey. Psychopharmacology, 2003, Volume: 167, Issue:2 Topics: Animals; Benzeneacetamides; Conditioning, Operant; Dextrorphan; Discrimination Learning; Dose-Response Relationship, Drug; Generalization, Psychological; Levorphanol; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Pyrrolidines; Receptors, Opioid; Saimiri; Substance Withdrawal Syndrome	2003
Regulation of RGS proteins by chronic morphine in rat locus coeruleus. The European journal of neuroscience, 2003, Volume: 17, Issue:5 Topics: Animals; Blotting, Western; Immunohistochemistry; In Situ Hybridization; Locus Coeruleus; Male; Membrane Potentials; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Neurons; Organ Culture Techniques; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; RGS Proteins; RNA, Messenger; Substance Withdrawal Syndrome	2003
Reinstatement of ethanol-seeking behavior by drug cues following single versus multiple ethanol intoxication in the rat: effects of naltrexone. Psychopharmacology, 2003, Volume: 168, Issue:1-2 Topics: Alcoholic Intoxication; Animals; Behavior, Addictive; Cues; Ethanol; Male; Naltrexone; Rats; Rats, Wistar; Substance Withdrawal Syndrome	2003
The effect of clonidine on gastrointestinal side effects associated with ultra-rapid opioid detoxification. Anesthesia and analgesia, 2003, Volume: 96, Issue:5 Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Diarrhea; Female; Gastrointestinal Diseases; Humans; Hypnotics and Sedatives; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Nausea; Opioid-Related Disorders; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome; Vomiting	2003
Enhanced binding of nor-binaltorphimine to kappa-opioid receptors in rats dependent on butorphanol. Journal of neuroscience research, 2003, Jun-15, Volume: 72, Issue:6 Topics: Animals; Brain; Butorphanol; Dose-Response Relationship, Drug; Male; Naltrexone; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Substance-Related Disorders	2003
Opiate withdrawal induces Narp in the extended amygdala. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:9 Topics: Amygdala; Analgesics; Animals; C-Reactive Protein; Cell Count; Clonidine; Dose-Response Relationship, Drug; Immunohistochemistry; Male; Naloxone; Naltrexone; Narcotic Antagonists; Nerve Tissue Proteins; Nucleus Accumbens; Opioid-Related Disorders; Rats; Rats, Sprague-Dawley; Septal Nuclei; Substance Withdrawal Syndrome	2003
Morphine withdrawal precipitated by specific mu, delta or kappa opioid receptor antagonists: a c-Fos protein study in the rat central nervous system. The European journal of neuroscience, 2003, Volume: 17, Issue:11 Topics: Animals; Behavior, Animal; Cell Count; Central Nervous System; Gene Expression Regulation; Immunohistochemistry; Male; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Narcotics; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome	2003
Effect of innappropriate naltrexone use in a heroin misuser. Emergency medicine journal : EMJ, 2003, Volume: 20, Issue:4 Topics: Adult; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Psychomotor Agitation; Substance Withdrawal Syndrome	2003
Emergency department presentations of naltrexone-accelerated detoxification. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2003, Volume: 10, Issue:8 Topics: Adolescent; Adult; Cohort Studies; Emergency Service, Hospital; Female; Hospital Mortality; Humans; Inactivation, Metabolic; Male; Middle Aged; Morbidity; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies; Substance Withdrawal Syndrome	2003
kappa-Opioid withdrawal in Planaria. Neuroscience letters, 2003, Oct-09, Volume: 349, Issue:3 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adaptation, Physiological; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Hydrogen-Ion Concentration; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Osmolar Concentration; Planarians; Reaction Time; Receptors, Opioid, kappa; Substance Withdrawal Syndrome	2003
Cocaine and other indirect-acting monoamine agonists differentially attenuate a naltrexone discriminative stimulus in morphine-treated rhesus monkeys. The Journal of pharmacology and experimental therapeutics, 2004, Volume: 308, Issue:1 Topics: Amphetamine; Animals; Biogenic Monoamines; Cocaine; Discrimination Learning; Disease Models, Animal; Dopamine Agents; Dopamine Uptake Inhibitors; Drug Interactions; Imipramine; Macaca mulatta; Morphine; Morphine Dependence; Naltrexone; Narcotics; Substance Withdrawal Syndrome	2004
Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. The Journal of pharmacology and experimental therapeutics, 2004, Volume: 308, Issue:2 Topics: Adenylyl Cyclases; Animals; Brain; Disease Models, Animal; Guanosine 5'-O-(3-Thiotriphosphate); Male; Mice; Mice, Inbred ICR; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Receptors, Opioid, mu; Signal Transduction; Substance Withdrawal Syndrome; Sulfur Radioisotopes	2004
Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users. Drug and alcohol review, 2003, Volume: 22, Issue:4 Topics: Adult; Buprenorphine; Emergency Medical Services; Female; Humans; Inactivation, Metabolic; Male; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Severity of Illness Index; Substance Abuse, Intravenous; Substance Withdrawal Syndrome	2003
[Detoxification in withdrawal state in methadone maintenance patients]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2003, Volume: 103, Issue:11 Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Data Interpretation, Statistical; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Substance Withdrawal Syndrome	2003
Unexpected delirium during Rapid Opioid Detoxification (ROD). Journal of addictive diseases, 2004, Volume: 23, Issue:1 Topics: Adult; Alcohol Withdrawal Delirium; Clonidine; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Inactivation, Metabolic; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome	2004
Potentiated startle and hyperalgesia during withdrawal from acute morphine: effects of multiple opiate exposures. Psychopharmacology, 2004, Volume: 176, Issue:3-4 Topics: Acoustic Stimulation; Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Hyperalgesia; Male; Morphine; Naltrexone; Narcotic Antagonists; Pain Measurement; Rats; Rats, Sprague-Dawley; Reflex, Startle; Substance Withdrawal Syndrome	2004
The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats. Behavioural pharmacology, 2004, Volume: 15, Issue:4 Topics: Acamprosate; Animals; Choice Behavior; Ethanol; Male; Memantine; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Saccharin; Substance Withdrawal Syndrome; Sweetening Agents; Taurine	2004
Chronic very low dose naltrexone administration attenuates opioid withdrawal expression. Biological psychiatry, 2004, Aug-15, Volume: 56, Issue:4 Topics: Analysis of Variance; Animals; Behavior, Animal; Blotting, Western; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Drug Administration Schedule; Immunohistochemistry; Locus Coeruleus; Male; Naltrexone; Narcotic Antagonists; Narcotics; Neostriatum; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome	2004
Monoaminergic drugs and directly observable signs of LAAM withdrawal in rhesus monkeys. Behavioural pharmacology, 2005, Volume: 16, Issue:1 Topics: Adrenergic alpha-Agonists; Amphetamine; Analgesics, Opioid; Animals; Antidepressive Agents, Tricyclic; Biogenic Monoamines; Clonidine; Cocaine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Female; Haloperidol; Imipramine; Macaca mulatta; Male; Methadyl Acetate; Muscle Rigidity; Naltrexone; Narcotic Antagonists; Respiratory Mechanics; Salivation; Substance Withdrawal Syndrome	2005
Sensitization to morphine withdrawal in guinea-pigs. European journal of pharmacology, 2005, Feb-21, Volume: 509, Issue:2-3 Topics: Amygdala; Analgesics, Opioid; Analysis of Variance; Animals; Behavior, Animal; Body Weight; Brain Chemistry; Cerebral Cortex; Guinea Pigs; Hippocampus; Hypothalamus; Immunohistochemistry; Male; Morphine; Motor Activity; Naltrexone; Proto-Oncogene Proteins c-fos; Rats; Substance Withdrawal Syndrome; Telencephalon; Time Factors	2005
Naltrexone treatment of combined alcohol and opioid dependence: deterioration of co-morbid major depression. Pharmacopsychiatry, 2005, Volume: 38, Issue:2 Topics: Alcoholism; Amitriptyline; Depressive Disorder, Major; Ethanol; Humans; Male; Middle Aged; Morphine; Morphine Dependence; Naltrexone; Narcotics; Severity of Illness Index; Substance Withdrawal Syndrome	2005
Inhibitory control of the acute mu-withdrawal response by indirectly activated adenosine A1 and kappa-opioid systems in the Guinea-pig ileum; reversal by cholecystokinin. Neurotoxicology, 2005, Volume: 26, Issue:5 Topics: Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Analgesics, Opioid; Animals; Cholecystokinin; Guinea Pigs; Ileum; In Vitro Techniques; Male; Muscle, Smooth; Naloxone; Naltrexone; Narcotic Antagonists; Opioid Peptides; Receptor, Adenosine A1; Receptors, Opioid, kappa; Receptors, Opioid, mu; Substance Withdrawal Syndrome; Theophylline	2005
Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence. British journal of pharmacology, 2005, Volume: 145, Issue:7 Topics: Animals; Behavior, Animal; Body Weight; Brain; Diprenorphine; Dose-Response Relationship, Drug; Male; Mice; Morphine; Morphine Dependence; Naloxone; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Tremor	2005
Measurement of symptom withdrawal severity in a 24-hour period after the anesthesia-assisted rapid opiate detoxification procedure. The American journal of drug and alcohol abuse, 2005, Volume: 31, Issue:2 Topics: Adult; Anesthetics, Intravenous; Clinical Protocols; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Inactivation, Metabolic; Injections, Subcutaneous; Male; Naltrexone; Narcotics; Opioid-Related Disorders; Propofol; Retrospective Studies; Severity of Illness Index; Substance Withdrawal Syndrome; Surveys and Questionnaires	2005
Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology, 2005, Volume: 181, Issue:3 Topics: Animals; Avoidance Learning; Conditioning, Classical; Dose-Response Relationship, Drug; Female; Injections, Subcutaneous; Morphine Dependence; Motivation; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Orientation; Oxycodone; Rats; Rats, Sprague-Dawley; Reward; Substance Withdrawal Syndrome	2005
Methods of detoxification and their role in treating patients with opioid dependence. JAMA, 2005, Aug-24, Volume: 294, Issue:8 Topics: Anesthesia, General; Buprenorphine; Clonidine; Female; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Failure	2005
Barium potentiates the conditioned aversion to, but not the somatic signs of, morphine withdrawal in mice. European journal of pharmacology, 2005, Sep-20, Volume: 519, Issue:3 Topics: Animals; Barium; Behavior, Animal; Cerebral Cortex; Conditioning, Operant; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Male; Mice; Mice, Inbred ICR; Morphine; Naltrexone; Narcotic Antagonists; Norepinephrine; Prosencephalon; Substance Withdrawal Syndrome	2005
Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa. Life sciences, 2005, Nov-19, Volume: 78, Issue:1 Topics: Analgesics; Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Drug Tolerance; Injections, Subcutaneous; Male; Mice; Mitragyna; Models, Molecular; Morphinans; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Pain Measurement; Reaction Time; Secologanin Tryptamine Alkaloids; Substance Withdrawal Syndrome; Thailand	2005
Constitutive opioid receptor activation: a prerequisite mechanism involved in acute opioid withdrawal. Addiction biology, 2005, Volume: 10, Issue:2 Topics: Acute Disease; Animals; Biotransformation; Dogs; Evoked Potentials, Somatosensory; Naltrexone; Narcotics; Protein Kinase C; Receptors, Opioid; Somatoform Disorders; Substance Withdrawal Syndrome; Sufentanil	2005
Drug treatment for alcoholism today. The Harvard mental health letter, 2005, Volume: 22, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Disulfiram; Fructose; Humans; Naltrexone; Substance Withdrawal Syndrome; Taurine; Topiramate	2005
Adolescent opioid abuse. Archives of general psychiatry, 2005, Volume: 62, Issue:10 Topics: Adolescent; Adolescent Behavior; Behavior Therapy; Buprenorphine; Humans; Hydrocodone; Naltrexone; Opioid-Related Disorders; Patient Compliance; Substance Withdrawal Syndrome; Treatment Outcome; United States	2005
Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey. The Journal of pharmacology and experimental therapeutics, 2006, Volume: 316, Issue:2 Topics: Animals; Binding Sites; Female; In Vitro Techniques; Ligands; Macaca mulatta; Male; Morphine Dependence; Naltrexone; Narcotic Antagonists; Radioligand Assay; Receptors, Opioid, mu; Substance Withdrawal Syndrome; Thalamus	2006
Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine. European journal of pharmacology, 2005, Nov-21, Volume: 525, Issue:1-3 Topics: Animals; Brain; Drug Administration Routes; Female; Ibogaine; Locus Coeruleus; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome	2005
Elevated mu-opioid receptor expression in the nucleus of the solitary tract accompanies attenuated withdrawal signs after chronic low dose naltrexone in opiate-dependent rats. Journal of neuroscience research, 2006, Feb-15, Volume: 83, Issue:3 Topics: Animals; Behavior, Animal; Blotting, Western; CREB-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Interactions; Gene Expression; Male; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Prosencephalon; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Solitary Nucleus; Substance Withdrawal Syndrome; Time Factors	2006
Motivational control of heroin seeking by conditioned stimuli associated with withdrawal and heroin taking by rats. Behavioral neuroscience, 2006, Volume: 120, Issue:1 Topics: Animals; Conditioning, Psychological; Food Preferences; Heroin; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Substance Withdrawal Syndrome; Sucrose; Time Factors	2006
Heroin detoxification. JAMA, 2006, Feb-22, Volume: 295, Issue:8 Topics: Anesthesia, General; Buprenorphine; Clonidine; Drug Therapy, Combination; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome	2006
Heroin detoxification. JAMA, 2006, Feb-22, Volume: 295, Issue:8 Topics: Anesthesia, General; Buprenorphine; Clonidine; Drug Therapy, Combination; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome	2006
Detoxification and treating opioid dependence. JAMA, 2006, Feb-22, Volume: 295, Issue:8 Topics: Anesthesia, General; Buprenorphine; Clonidine; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome	2006
Detoxification and treating opioid dependence. JAMA, 2006, Feb-22, Volume: 295, Issue:8 Topics: Anesthesia, General; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome	2006
Obviation of opioid withdrawal syndrome by concomitant administration of naltrexone in microgram doses: two psychonautic bioassays. Journal of psychoactive drugs, 2006, Volume: 38, Issue:1 Topics: Codeine; Half-Life; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome	2006
Anticonvulsive effects of kappa-opioid receptor modulation in an animal model of ethanol withdrawal. Genes, brain, and behavior, 2006, Volume: 5, Issue:6 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Alcohol-Induced Disorders, Nervous System; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Anticonvulsants; Brain; Central Nervous System Depressants; Disease Models, Animal; Drug Interactions; Drug Synergism; Ethanol; Male; Naltrexone; Receptors, Opioid, kappa; Seizures; Species Specificity; Substance Withdrawal Syndrome; Treatment Outcome	2006
Activators of potassium M currents have anticonvulsant actions in two rat models of encephalitis. European journal of pharmacology, 2007, Jan-19, Volume: 555, Issue:1 Topics: Aminopyridines; Analgesics; Animals; Anticonvulsants; Borna Disease; Encephalitis, Viral; Herpes Simplex; Herpesvirus 1, Human; Male; Naloxone; Naltrexone; Narcotic Antagonists; Potassium; Rats; Rats, Inbred Lew; Receptors, Opioid, delta; Seizures; Substance Withdrawal Syndrome	2007
Naltrexone-assisted rapid methadone discontinuation: a pilot study. European addiction research, 2007, Volume: 13, Issue:1 Topics: Adult; Drug Evaluation, Preclinical; Female; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Pilot Projects; Substance Withdrawal Syndrome; Treatment Outcome	2007
Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082). European journal of pharmacology, 2007, Jul-02, Volume: 566, Issue:1-3 Topics: Analgesics, Opioid; Animals; Arthritis, Experimental; Benzomorphans; Female; Hot Temperature; Macaca mulatta; Male; Mice; Mice, Inbred ICR; Morphine Dependence; Naltrexone; Narcotic Antagonists; Pain; Rats; Rats, Inbred Lew; Receptors, Opioid, delta; Stereoisomerism; Substance Withdrawal Syndrome	2007
Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2007, Volume: 9, Issue:5 Topics: Adult; Attitude to Health; Factor Analysis, Statistical; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Nicotine; Patient Compliance; Psychometrics; Reproducibility of Results; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires; Tobacco Use Disorder	2007
Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:3 Topics: Administration, Inhalation; Alcoholism; Animals; Central Nervous System Depressants; Conditioning, Operant; Data Interpretation, Statistical; Dynorphins; Ethanol; Injections, Intraventricular; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Self Administration; Substance Withdrawal Syndrome	2008
Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:3 Topics: Adult; Alcoholism; Analgesics, Opioid; Data Interpretation, Statistical; Female; Fentanyl; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Opioid, delta; Receptors, Opioid, mu; Substance Withdrawal Syndrome; Temperance	2008
Overcoming opioid blockade from depot naltrexone (Prodetoxon). Addiction (Abingdon, England), 2007, Volume: 102, Issue:7 Topics: Adult; Drug Implants; Heroin Dependence; Humans; Inactivation, Metabolic; Male; Naltrexone; Narcotic Antagonists; Secondary Prevention; Substance Withdrawal Syndrome	2007
Does naltrexone affect craving in abstinent opioid-dependent patients? Addiction biology, 2007, Volume: 12, Issue:2 Topics: Adult; Female; Heroin; Heroin Dependence; Humans; Longitudinal Studies; Male; Methadone; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Secondary Prevention; Substance Abuse Detection; Substance Withdrawal Syndrome; Surveys and Questionnaires	2007
Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice. Brain research, 2007, Sep-05, Volume: 1167 Topics: Analgesics, Opioid; Animals; Chronic Disease; Dipeptides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; G(M1) Ganglioside; Hyperalgesia; Male; Mice; Morphine; Morphine Dependence; Naloxone; Naltrexone; Narcotic Antagonists; Nociceptors; Opioid Peptides; Receptors, Opioid, kappa; Substance Withdrawal Syndrome	2007
Mu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy. The Journal of pharmacology and experimental therapeutics, 2007, Volume: 323, Issue:2 Topics: Animals; Dose-Response Relationship, Drug; Male; Mice; Morphine; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Substance Withdrawal Syndrome; Up-Regulation	2007
GABAergic medications for treating alcohol dependence. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:5 Topics: Alcoholism; Baclofen; Drug Therapy, Combination; GABA Agonists; gamma-Aminobutyric Acid; Humans; Hydroxybutyrates; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Receptors, GABA-B; Substance Withdrawal Syndrome; Temperance	2007
The kappa-opioid receptor antagonist nor-BNI inhibits cocaine and amphetamine, but not cannabinoid (WIN 52212-2), abstinence-induced withdrawal in planarians: an instance of 'pharmacologic congruence'. Brain research, 2008, Feb-08, Volume: 1193 Topics: Amphetamine; Analgesics; Analysis of Variance; Animals; Behavior, Animal; Benzoxazines; Cocaine; Disease Models, Animal; Dopamine Uptake Inhibitors; Drug Interactions; Morpholines; Naltrexone; Naphthalenes; Narcotic Antagonists; Planarians; Substance Withdrawal Syndrome; Time Factors	2008
Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine-dependent mice. European journal of pharmacology, 2008, Mar-31, Volume: 583, Issue:1 Topics: Animals; Binding, Competitive; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Male; Mice; Mice, Inbred ICR; Morphinans; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Narcotics; Pain Measurement; Pyrroles; Receptors, Opioid, mu; Substance Withdrawal Syndrome	2008
Acute and chronic heroin dependence in mice: contribution of opioid and excitatory amino acid receptors. European journal of pharmacology, 2008, May-31, Volume: 586, Issue:1-3 Topics: Acute Disease; Animals; Behavior, Animal; Benzylidene Compounds; Chronic Disease; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Heroin Dependence; Male; Mice; Naloxone; Naltrexone; Narcotic Antagonists; Receptors, AMPA; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Time Factors	2008
Low dose naltrexone administration in morphine dependent rats attenuates withdrawal-induced norepinephrine efflux in forebrain. Progress in neuro-psychopharmacology & biological psychiatry, 2008, May-15, Volume: 32, Issue:4 Topics: Animals; Area Under Curve; Brain Chemistry; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dopamine beta-Hydroxylase; Electrochemistry; Extracellular Space; Immunoenzyme Techniques; Male; Microdialysis; Morphine Dependence; Naltrexone; Narcotic Antagonists; Norepinephrine; Prosencephalon; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome	2008
Unplanned admissions to two Sydney public hospitals after naltrexone implants. The Medical journal of Australia, 2008, Apr-21, Volume: 188, Issue:8 Topics: Adult; Drug Implants; Female; Heroin Dependence; Hospitals, Public; Humans; Incidence; Male; Naltrexone; Narcotic Antagonists; New South Wales; Patient Admission; Retrospective Studies; Substance Withdrawal Syndrome; Time Factors	2008
Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception. Psychopharmacology, 2008, Volume: 199, Issue:2 Topics: Analgesics; Analgesics, Opioid; Animals; Data Interpretation, Statistical; Discrimination, Psychological; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Female; Heroin; Hot Temperature; Hypnotics and Sedatives; Macaca mulatta; Male; Midazolam; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Pain Measurement; Receptors, Opioid, mu; Substance Withdrawal Syndrome	2008
Clonidine hydrochloride detoxification from methadone treatment--the value of naltrexone aftercare. Advances in alcohol & substance abuse, 1984,Spring, Volume: 3, Issue:3 Topics: Adult; Aftercare; Attitude to Health; Clonidine; Female; Follow-Up Studies; Humans; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	1984
Clonidine and opiate withdrawal. Lancet (London, England), 1980, Nov-15, Volume: 2, Issue:8203 Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	1980
Stereospecific accumulation of dihydromorphine and naltrexone by corpus striatal slices of morphine-dependent mice. Neuropharmacology, 1982, Volume: 21, Issue:1 Topics: Animals; Binding, Competitive; Corpus Striatum; Dihydromorphine; Humans; In Vitro Techniques; Male; Mice; Morphine Dependence; Morphine Derivatives; Naloxone; Naltrexone; Receptors, Opioid; Stereoisomerism; Substance Withdrawal Syndrome	1982
Methadone-induced endorphin dysfunction in addicts. NIDA research monograph, 1982, Volume: 41 Topics: Adrenocorticotropic Hormone; Brain; Endorphins; Humans; Hydrocortisone; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Receptors, Opioid; Substance Withdrawal Syndrome	1982
Recent advances in opiate detoxification: clonidine and lofexidine. NIDA research monograph, 1983, Volume: 43 Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	1983
Assessment and extinction of conditioned withdrawal-like responses in an integrated treatment for opiate dependence. NIDA research monograph, 1984, Volume: 55 Topics: Adult; Conditioning, Classical; Emotions; Extinction, Psychological; Female; Humans; Male; Naltrexone; Opioid-Related Disorders; Skin Temperature; Substance Withdrawal Syndrome; Time Factors	1984
Naltrexone: a clinical perspective. The Journal of clinical psychiatry, 1984, Volume: 45, Issue:9 Pt 2 Topics: Adult; Alcohol Drinking; Ambulatory Care; Follow-Up Studies; Heroin Dependence; Hospitalization; Humans; Middle Aged; Naloxone; Naltrexone; Opioid-Related Disorders; Patient Dropouts; Social Support; Substance Withdrawal Syndrome	1984
Strategies to improve compliance with narcotic antagonists. The American journal of drug and alcohol abuse, 1984, Volume: 10, Issue:2 Topics: Combined Modality Therapy; Humans; Life Style; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Patient Compliance; Patient Dropouts; Research; Social Support; Substance Withdrawal Syndrome	1984
Methadone and naltrexone in the treatment of heroin dependence. The Psychiatric clinics of North America, 1984, Volume: 7, Issue:4 Topics: Heroin Dependence; Humans; Methadone; Naloxone; Naltrexone; Psychotherapy; Substance Withdrawal Syndrome; Time Factors	1984
Stress induced alteration of opiate withdrawal. Drug and alcohol dependence, 1984, Volume: 13, Issue:3 Topics: Animals; Body Weight; Humans; Male; Morphine; Naltrexone; Rats; Rats, Inbred Strains; Stress, Physiological; Substance Withdrawal Syndrome	1984
An antiabsorptive basis for precipitated withdrawal diarrhea in morphine-dependent rats. The Journal of pharmacology and experimental therapeutics, 1984, Volume: 228, Issue:2 Topics: Animals; Atropine; Biological Transport; Diarrhea; Gastrointestinal Motility; Hexamethonium Compounds; Humans; Intestinal Absorption; Male; Morphine; Morphine Dependence; Naltrexone; Quaternary Ammonium Compounds; Rats; Rats, Inbred Lew; Substance Withdrawal Syndrome; Water-Electrolyte Balance	1984
Prolonged excretion of morphine in rats during protracted abstinence: lack of effect of naltrexone. The Journal of pharmacology and experimental therapeutics, 1983, Volume: 224, Issue:2 Topics: Animals; Body Weight; Gas Chromatography-Mass Spectrometry; Humans; Male; Morphine; Naloxone; Naltrexone; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome	1983
A preliminary description of acute physical dependence on morphine in the vervet monkey. Pharmacology, biochemistry, and behavior, 1983, Volume: 18, Issue:2 Topics: Animals; Behavior, Animal; Catheterization; Chlorocebus aethiops; Humans; Male; Morphine; Morphine Dependence; Naloxone; Naltrexone; Substance Withdrawal Syndrome	1983
Clonidine hydrochloride detoxification from methadone treatments: the value of naltrexone aftercare. NIDA research monograph, 1981, Volume: 34 Topics: Adolescent; Clonidine; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Opium; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors	1981
Central regulation of intestinal function: morphine withdrawal diarrhea. Proceedings of the Western Pharmacology Society, 1982, Volume: 25 Topics: Animals; Body Weight; Diarrhea; Female; Humans; Intestines; Morphine Dependence; Nalorphine; Naltrexone; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome	1982
Endorphin levels in opioid-dependent human subjects: a longitudinal study. Annals of the New York Academy of Sciences, 1982, Volume: 398 Topics: Adult; Endorphins; Humans; Male; Methadone; Middle Aged; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	1982
Outpatient opiate detoxification with clonidine. The Journal of clinical psychiatry, 1982, Volume: 43, Issue:6 Pt 2 Topics: Ambulatory Care; Clonidine; Double-Blind Method; Drug Therapy, Combination; Heroin Dependence; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	1982
Naltrexone effects on morphine and food self-administration in morphine-dependent rhesus monkeys. The Journal of pharmacology and experimental therapeutics, 1981, Volume: 218, Issue:2 Topics: Animals; Conditioning, Operant; Food; Humans; Macaca mulatta; Male; Morphine; Morphine Dependence; Naloxone; Naltrexone; Self Administration; Substance Withdrawal Syndrome	1981
Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. European journal of pharmacology, 1982, Mar-12, Volume: 78, Issue:3 Topics: Animals; Central Nervous System; Diarrhea; Digestive System; Dogs; Female; Humans; Male; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Nociceptors; Rats; Rats, Inbred Strains; Species Specificity; Substance Withdrawal Syndrome	1982
The clinical use of clonidine in outpatient detoxification from opiates. Progress in clinical and biological research, 1981, Volume: 71 Topics: Clonidine; Dose-Response Relationship, Drug; Heroin Dependence; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Self Administration; Substance Withdrawal Syndrome	1981
Naltrexone: a short-term treatment for opiate dependence. The American journal of drug and alcohol abuse, 1981, Volume: 8, Issue:3 Topics: Adult; Employment; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Opioid-Related Disorders; Outcome and Process Assessment, Health Care; Patient Dropouts; Substance Withdrawal Syndrome; Time Factors	1981
The naloxone test for opiate dependence. Clinical pharmacology and therapeutics, 1980, Volume: 27, Issue:4 Topics: Humans; Injections, Intramuscular; Injections, Intravenous; Methadyl Acetate; Naloxone; Naltrexone; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome	1980
Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proceedings of the National Academy of Sciences of the United States of America, 1995, Nov-07, Volume: 92, Issue:23 Topics: Analgesia; Analgesics, Opioid; Animals; Behavior, Animal; Culture Techniques; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolerance; Electrophysiology; Ganglia, Spinal; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Neurons, Afferent; Pain Measurement; Substance Withdrawal Syndrome; Substance-Related Disorders	1995
Effects of naltrexone on morphine-induced tolerance and physical dependence and changes in cellular immune function in mice. Brain research, 1995, Aug-28, Volume: 690, Issue:1 Topics: Animals; B-Lymphocytes; Body Weight; Cell Division; Drug Implants; Drug Tolerance; Female; Immunity, Cellular; Killer Cells, Natural; Mice; Morphine; Morphine Dependence; Naltrexone; Substance Withdrawal Syndrome; T-Lymphocytes	1995
NMDA antagonists and clonidine block c-fos expression during morphine withdrawal. Synapse (New York, N.Y.), 1995, Volume: 20, Issue:1 Topics: Animals; Clonidine; Dizocilpine Maleate; Gene Expression; Genes, fos; In Vitro Techniques; Isoquinolines; Male; Morphine; Naltrexone; Neural Pathways; Nucleic Acid Hybridization; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; RNA Probes; RNA, Messenger; Substance Withdrawal Syndrome	1995
Endogenous kappa-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release. Psychopharmacology, 1994, Volume: 115, Issue:1-2 Topics: Animals; Behavior, Animal; Biogenic Monoamines; Conditioning, Operant; Dopamine; Injections, Intraventricular; Limbic System; Male; Microdialysis; Morphine Dependence; Naloxone; Naltrexone; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reinforcement, Psychology; Substance Withdrawal Syndrome	1994
[USA approves of a new drug that decreases the craving for alcohol]. Lakartidningen, 1995, Mar-08, Volume: 92, Issue:10 Topics: Alcoholism; Drug Approval; Humans; Naltrexone; Substance Withdrawal Syndrome; United States	1995
The kappa-opioid receptor agonist U50,488H induces acute physical dependence in guinea-pigs. European journal of pharmacology, 1993, Sep-14, Volume: 241, Issue:2-3 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Opioid; Animals; Behavior, Animal; Female; Guinea Pigs; Ileum; In Vitro Techniques; Male; Morphine Dependence; Motor Activity; Muscle Contraction; Muscle, Smooth; Naloxone; Naltrexone; Pyrrolidines; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Substance-Related Disorders	1993
Effects of naltrexone pellet implantation on morphine tolerance and physical dependence in the rat. General pharmacology, 1994, Volume: 25, Issue:1 Topics: Analgesia; Animals; Body Temperature; Dose-Response Relationship, Drug; Drug Implants; Drug Interactions; Drug Tolerance; Male; Morphine; Naltrexone; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors; Weight Loss	1994
Effect of morphine tolerance and abstinence on the binding of [3H]naltrexone to discrete brain regions and spinal cord of the rat. General pharmacology, 1994, Volume: 25, Issue:2 Topics: Analgesics; Animals; Brain; Drug Implants; Drug Tolerance; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Male; Membranes; Morphine; Morphine Dependence; Naltrexone; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Opioid, mu; Spinal Cord; Substance Withdrawal Syndrome	1994
A 24-h inpatient detoxification treatment for heroin addicts: a preliminary investigation. Drug and alcohol dependence, 1994, Volume: 35, Issue:2 Topics: Administration, Oral; Adult; Conscious Sedation; Drug Administration Schedule; Follow-Up Studies; Guanfacine; Heroin Dependence; Humans; Intensive Care Units; Length of Stay; Male; Midazolam; Naltrexone; Neurologic Examination; Patient Admission; Premedication; Substance Abuse Detection; Substance Withdrawal Syndrome	1994
Involvement of kappa-opioid receptors in opioid dependence/withdrawal: studies using butorphanol. European journal of pharmacology, 1994, May-12, Volume: 257, Issue:1-2 Topics: Animals; Butorphanol; Injections, Intraventricular; Male; Naloxone; Naltrexone; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Substance-Related Disorders	1994
Dependence on tramadol. The Clinical investigator, 1993, Volume: 72, Issue:1 Topics: Adult; Drug Tolerance; Euphoria; Female; Humans; Naltrexone; Seizures; Substance Withdrawal Syndrome; Substance-Related Disorders; Tramadol	1993
Effects of nor-binaltorphimine on butorphanol dependence. European journal of pharmacology, 1993, Aug-03, Volume: 239, Issue:1-3 Topics: Animals; Benzeneacetamides; Body Temperature; Body Weight; Butorphanol; Diarrhea; Down-Regulation; Drug Administration Schedule; Escape Reaction; Male; Naltrexone; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Substance-Related Disorders; Tremor	1993
Relative involvement of supraspinal and spinal mu opioid receptors in morphine dependence in mice. Life sciences, 1993, Volume: 52, Issue:12 Topics: Animals; Brain; Cerebral Ventricles; Diarrhea; Injections, Intraventricular; Injections, Spinal; Male; Mice; Morphine Dependence; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Spinal Cord; Substance Withdrawal Syndrome	1993
Involvement of delta 2 opioid receptors in the development of morphine dependence in mice. The Journal of pharmacology and experimental therapeutics, 1993, Volume: 264, Issue:3 Topics: Animals; Enkephalin, Leucine; Isothiocyanates; Male; Mice; Morphinans; Morphine Dependence; Naloxone; Naltrexone; Receptors, Opioid, delta; Substance Withdrawal Syndrome; Thiocyanates	1993
Opioid antagonists and butorphanol dependence. Pharmacology, biochemistry, and behavior, 1993, Volume: 44, Issue:3 Topics: Animals; Behavior, Animal; Butorphanol; Indoles; Injections, Intraventricular; Male; Morphinans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu; Substance Withdrawal Syndrome	1993
Withdrawal contractures of guinea-pig isolated ileum after acute activation of kappa-opioid receptors. British journal of pharmacology, 1993, Volume: 109, Issue:1 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Clonidine; Guinea Pigs; Ileum; In Vitro Techniques; Male; Morphine; Muscle Contraction; Muscle, Smooth; Naloxone; Naltrexone; Nifedipine; Pyrrolidines; Receptors, Opioid, kappa; Substance Withdrawal Syndrome	1993
Heroin withdrawal precipitated by nonmedical use of naltrexone. The American journal of psychiatry, 1993, Volume: 150, Issue:2 Topics: Adult; Heroin; Heroin Dependence; Humans; Male; Naltrexone; Self Medication; Substance Withdrawal Syndrome	1993
Ultrashort noninvasive opiate detoxification. The American journal of psychiatry, 1993, Volume: 150, Issue:5 Topics: Adult; Heroin Dependence; Humans; Male; Midazolam; Naloxone; Naltrexone; Ondansetron; Substance Withdrawal Syndrome; Time Factors	1993
Attenuation of morphine tolerance and dependence with the highly selective delta-opioid receptor antagonist TIPP[psi]. European journal of pharmacology, 1995, Nov-03, Volume: 286, Issue:1 Topics: Animals; Behavior, Animal; Morphine Dependence; Naloxone; Naltrexone; Narcotic Antagonists; Oligopeptides; Rats; Receptors, Opioid, delta; Substance Withdrawal Syndrome; Tetrahydroisoquinolines	1995
Induction of chronic Fos-related antigens in rat brain by chronic morphine administration. Molecular pharmacology, 1996, Volume: 49, Issue:4 Topics: Animals; Blotting, Western; Brain; DNA-Binding Proteins; Fos-Related Antigen-2; Male; Morphine; Naltrexone; Narcotics; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Transcription Factor AP-1; Transcription Factors	1996
Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. The Journal of pharmacology and experimental therapeutics, 1996, Volume: 276, Issue:2 Topics: Adult; Analgesics, Opioid; Buprenorphine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome	1996
Spinal cord mechanisms of opioid tolerance and dependence: Fos-like immunoreactivity increases in subpopulations of spinal cord neurons during withdrawal [corrected]. Neuroscience, 1996, Volume: 72, Issue:1 Topics: Analgesics, Opioid; Animals; Drug Implants; Drug Tolerance; Male; Morphine; Naltrexone; Narcotic Antagonists; Neurons; Opioid-Related Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Spinal Cord; Substance Withdrawal Syndrome	1996
Distribution of c-Fos in guinea-pig brain following morphine withdrawal. Brain research, 1996, Apr-22, Volume: 717, Issue:1-2 Topics: Analgesics, Opioid; Animals; Brain Chemistry; Female; Guinea Pigs; Locomotion; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Proto-Oncogene Proteins c-fos; Substance Withdrawal Syndrome	1996
Role of delta-opioid receptors in mediating the aversive stimulus effects of morphine withdrawal in the rat. European journal of pharmacology, 1996, Apr-04, Volume: 300, Issue:1-2 Topics: Animals; Dose-Response Relationship, Drug; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Substance Withdrawal Syndrome	1996
Ontogeny of morphine withdrawal in the rat. Behavioral neuroscience, 1995, Volume: 109, Issue:6 Topics: Age Factors; Animals; Arousal; Female; Humans; Infant, Newborn; Injections, Intraperitoneal; Male; Morphine; Morphine Dependence; Motor Activity; Naltrexone; Narcotic Antagonists; Neonatal Abstinence Syndrome; Neurologic Examination; Rats; Substance Withdrawal Syndrome	1995
Repeated naltrexone administration accelerates resolution of morphine somatic withdrawal signs in morphine-dependent rats. European journal of pharmacology, 1996, Apr-22, Volume: 301, Issue:1-3 Topics: Animals; Behavior, Animal; Male; Morphine Dependence; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome	1996
Preprothyrotropin-releasing hormone mRNA in the rat central gray is strongly and persistently induced during morphine withdrawal. Neuropeptides, 1996, Volume: 30, Issue:3 Topics: Analgesics, Opioid; Animals; Brain; In Situ Hybridization; Male; Mesencephalon; Morphine; Naltrexone; Narcotic Antagonists; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substance Withdrawal Syndrome; Thalamus; Thyrotropin-Releasing Hormone; Up-Regulation	1996
Mu- and delta-opioid receptor antagonists precipitate similar withdrawal phenomena in butorphanol and morphine dependence. Neurochemical research, 1996, Volume: 21, Issue:1 Topics: Animals; Butorphanol; Drug Evaluation, Preclinical; Injections, Intraventricular; Locus Coeruleus; Male; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu; Somatostatin; Substance Withdrawal Syndrome	1996
Evidence for a role of nitric oxide of the central nervous system in morphine abstinence syndrome. Pharmacology, 1996, Volume: 52, Issue:2 Topics: Animals; Behavior, Animal; Central Nervous System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Injections, Intraventricular; Male; Mice; Morphine Dependence; Naltrexone; Narcotic Antagonists; Nitric Oxide; Nitric Oxide Synthase; Nitroarginine; omega-N-Methylarginine; Substance Withdrawal Syndrome	1996
Opiate withdrawal increases ProTRH gene expression in the ventrolateral column of the midbrain periaqueductal gray. Brain research, 1996, Aug-05, Volume: 729, Issue:1 Topics: Animals; Gene Expression Regulation; Immunohistochemistry; In Situ Hybridization; Male; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Neurons; Periaqueductal Gray; Protein Precursors; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Thyrotropin-Releasing Hormone	1996
Rapid opiate detoxification. The American journal of drug and alcohol abuse, 1996, Volume: 22, Issue:4 Topics: Adult; Anesthetics, Intravenous; Critical Care; Female; Heroin Dependence; Humans; Hypnotics and Sedatives; Length of Stay; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Neuromuscular Nondepolarizing Agents; Propofol; Respiration, Artificial; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Vecuronium Bromide	1996
A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1996, Volume: 15, Issue:5 Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Electrophysiology; In Vitro Techniques; Isoquinolines; Locus Coeruleus; Male; Morphine; Naltrexone; Narcotics; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Substance Withdrawal Syndrome; Tetrazoles	1996
Potential danger of nalmefene use in the emergency department. Annals of emergency medicine, 1997, Volume: 29, Issue:1 Topics: Emergency Service, Hospital; Heroin; Humans; Naltrexone; Narcotic Antagonists; Patient Discharge; Substance Withdrawal Syndrome	1997
Monoamine metabolism in the locus coeruleus measured concurrently with behavior during opiate withdrawal: an in vivo microdialysis study in freely moving rats. Journal of neurochemistry, 1997, Volume: 68, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Analgesics, Opioid; Animals; Behavior, Animal; Biogenic Monoamines; Hydroxyindoleacetic Acid; Locus Coeruleus; Male; Microdialysis; Monoamine Oxidase Inhibitors; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Pargyline; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome	1997
Experts debate merits of 1-day opiate detoxification under anesthesia. JAMA, 1997, Feb-05, Volume: 277, Issue:5 Topics: Anesthesia, General; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Abuse Treatment Centers; Substance Withdrawal Syndrome	1997
Chronic morphine and naltrexone fail to modify mu-opioid receptor mRNA levels in the rat brain. Brain research. Molecular brain research, 1997, Volume: 45, Issue:1 Topics: Animals; Brain; Corpus Striatum; DNA Primers; Drug Administration Schedule; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Male; Morphine; Naltrexone; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; RNA, Messenger; Substance Withdrawal Syndrome	1997
Increased release of excitatory amino acids in rat locus coeruleus in kappa-opioid agonist dependent rats precipitated by nor-binaltorphimine. Brain research, 1997, Apr-04, Volume: 753, Issue:1 Topics: Animals; Benzeneacetamides; Butorphanol; Drug Evaluation, Preclinical; Excitatory Amino Acids; Locus Coeruleus; Male; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Receptors, Opioid, mu; Substance Withdrawal Syndrome; Substance-Related Disorders	1997
Competitive and glycine/NMDA receptor antagonists attenuate withdrawal-induced behaviours and increased hippocampal acetylcholine efflux in morphine-dependent rats. Neuropharmacology, 1997, Volume: 36, Issue:2 Topics: Acetylcholine; Adrenergic alpha-Agonists; Animals; Behavior, Animal; Binding, Competitive; Clonidine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Hippocampus; In Vitro Techniques; Male; Microdialysis; Morphine Dependence; Naltrexone; Narcotic Antagonists; Pipecolic Acids; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, Glycine; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome	1997
Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain research, 1997, May-23, Volume: 757, Issue:2 Topics: Administration, Oral; Analgesics, Opioid; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Tolerance; Etorphine; Infusions, Parenteral; Male; Mice; Mice, Inbred Strains; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Narcotics; Nociceptors; Substance Withdrawal Syndrome; Substance-Related Disorders	1997
Ventilation in morphine-maintained rhesus monkeys. I: Effects of naltrexone and abstinence-associated withdrawal. The Journal of pharmacology and experimental therapeutics, 1997, Volume: 282, Issue:1 Topics: Animals; Dose-Response Relationship, Drug; Female; Macaca mulatta; Male; Morphine; Naltrexone; Narcotics; Respiration; Substance Withdrawal Syndrome	1997
Outpatient non-opioid detoxification for opioid withdrawal. Who is likely to benefit? The American journal on addictions, 1997,Summer, Volume: 6, Issue:3 Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Ambulatory Care Facilities; Clonidine; Female; GABA Modulators; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Oxazepam; Retrospective Studies; Substance Withdrawal Syndrome; Substance-Related Disorders; Treatment Outcome	1997
Precipitated morphine withdrawal induces a conditioned aversion in the preweaning rat. Pharmacology, biochemistry, and behavior, 1997, Volume: 57, Issue:4 Topics: Animals; Animals, Newborn; Avoidance Learning; Conditioning, Psychological; Female; Male; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Smell; Substance Withdrawal Syndrome	1997
Rapid opiate detoxification. Assessment is needed to exclude certain patients before detoxification. BMJ (Clinical research ed.), 1997, Sep-13, Volume: 315, Issue:7109 Topics: Adrenergic alpha-Agonists; Clonidine; Humans; Naltrexone; Narcotic Antagonists; Narcotics; Substance Withdrawal Syndrome; Substance-Related Disorders	1997
Nor-binaltorphimine precipitates withdrawal and excitatory amino acid release in the locus ceruleus of butorphanol--but not morphine-dependent rats. The Journal of pharmacology and experimental therapeutics, 1997, Volume: 283, Issue:2 Topics: Animals; Butorphanol; Excitatory Amino Acids; Locus Coeruleus; Male; Microdialysis; Morphine Dependence; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Substance Withdrawal Syndrome	1997
Addict died after rapid opiate detoxification. BMJ (Clinical research ed.), 1998, Jan-17, Volume: 316, Issue:7126 Topics: Anesthesia; Death, Sudden; Heroin Dependence; Humans; Inactivation, Metabolic; Male; Malpractice; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome	1998
Activation of coeruleospinal noradrenergic inhibitory controls during withdrawal from morphine in the rat. The Journal of neuroscience : the official journal of the Society for Neuroscience, 1998, Jun-01, Volume: 18, Issue:11 Topics: Animals; Antibodies, Monoclonal; Efferent Pathways; Immunotoxins; Locus Coeruleus; Male; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Neural Inhibition; Norepinephrine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins; Spinal Cord; Substance Withdrawal Syndrome	1998
Neonatal withdrawal following pre- and postnatal exposure to methadone in the rat. Pharmacology, biochemistry, and behavior, 1998, Volume: 60, Issue:1 Topics: Animals; Animals, Newborn; Behavior, Animal; Female; Humans; Infant, Newborn; Male; Methadone; Motor Activity; Naltrexone; Narcotic Antagonists; Neonatal Abstinence Syndrome; Pregnancy; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Vocalization, Animal	1998
Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results. Drug and alcohol dependence, 1998, Nov-01, Volume: 52, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Anesthesia, General; Clonidine; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Heroin Dependence; Humans; Hypnotics and Sedatives; Length of Stay; Male; Methadone; Midazolam; Naltrexone; Narcotic Antagonists; Neurologic Examination; Ondansetron; Substance Withdrawal Syndrome; Treatment Outcome	1998
The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropharmacology, 1999, Volume: 38, Issue:2 Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Bridged Bicyclo Compounds; Electrophysiology; Excitatory Amino Acid Agonists; Locus Coeruleus; Male; Membrane Potentials; Morphine; Morphine Dependence; Naltrexone; Neurons; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Substance Withdrawal Syndrome	1999
Heart rate variability and plasma catecholamines in patients during opioid detoxification. Journal of neurosurgical anesthesiology, 1999, Volume: 11, Issue:3 Topics: Adult; Analysis of Variance; Anesthetics, Intravenous; Blood Pressure; Electroencephalography; Epinephrine; Female; Heart Rate; Humans; Male; Naltrexone; Narcotic Antagonists; Norepinephrine; Opioid-Related Disorders; Propofol; Signal Processing, Computer-Assisted; Substance Withdrawal Syndrome; Sympathetic Nervous System; Sympathomimetics; Wakefulness	1999
The bed nucleus of the stria terminalis. A target site for noradrenergic actions in opiate withdrawal. Annals of the New York Academy of Sciences, 1999, Jun-29, Volume: 877 Topics: Amygdala; Animals; Axonal Transport; Caudate Nucleus; Male; Microinjections; Morphine Dependence; Naloxone; Naltrexone; Neurons; Norepinephrine; Oxidopamine; Propranolol; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Thalamus; Tyrosine 3-Monooxygenase	1999
Interactions between cholecystokinin and opioids in the isolated guinea-pig ileum. British journal of pharmacology, 1999, Volume: 127, Issue:4 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Guinea Pigs; Ileum; In Vitro Techniques; Male; Morphinans; Muscle Contraction; Naloxone; Naltrexone; Oligopeptides; Opioid Peptides; Receptor, Cholecystokinin A; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Receptors, Opioid; Sincalide; Substance Withdrawal Syndrome	1999
Is naltrexone a cure for heroin dependence? The Medical journal of Australia, 1999, Jul-05, Volume: 171, Issue:1 Topics: Australia; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Pilot Projects; Substance Withdrawal Syndrome	1999
Emergency therapeutical approach simulating ultrarapid opioid detoxification in methadone withdrawal precipitated by erroneous administration of naltrexone. European journal of emergency medicine : official journal of the European Society for Emergency Medicine, 1999, Volume: 6, Issue:2 Topics: Adult; Anesthetics, Intravenous; Emergencies; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Propofol; Substance Withdrawal Syndrome	1999
Serendipitous rapid detoxification from opiates: the importance of time-dependent processes. Addiction (Abingdon, England), 1999, Volume: 94, Issue:4 Topics: Adult; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Substance Withdrawal Syndrome; Time Factors	1999
Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. Journal of neurochemistry, 2000, Volume: 74, Issue:1 Topics: Animals; Behavior, Animal; Male; Morphine; Naltrexone; Narcotic Antagonists; Protein Isoforms; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Substance Withdrawal Syndrome	2000
Is there a pharmacological basis for therapy with rapid opioid detoxification? Lancet (London, England), 1999, Dec-11, Volume: 354, Issue:9195 Topics: Anesthesia, General; Animals; Conscious Sedation; Cyclic AMP Response Element-Binding Protein; Heroin Dependence; Humans; Mice; Mice, Knockout; Naloxone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Signal Transduction; Substance Withdrawal Syndrome; Treatment Outcome	1999
Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology, 2000, Volume: 118, Issue:2 Topics: Administration, Oral; Adult; Cholestasis; Chronic Disease; Female; Humans; Infusions, Intravenous; Naltrexone; Narcotic Antagonists; Pruritus; Substance Withdrawal Syndrome	2000
Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze. Psychopharmacology, 2000, Volume: 147, Issue:4 Topics: Acamprosate; Alcohol Deterrents; Animals; Anxiety; Central Nervous System Depressants; Ethanol; Exploratory Behavior; Male; Mice; Naltrexone; Substance Withdrawal Syndrome; Taurine	2000
Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: a prospective study in methadone, heroin, codeine and morphine addicts. Acta anaesthesiologica Scandinavica, 2000, Volume: 44, Issue:3 Topics: Adult; Anesthesia, General; Codeine; Female; Heroin Dependence; Humans; Male; Methadone; Morphine Dependence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prospective Studies; Substance Withdrawal Syndrome	2000
Short-acting NMDA receptor antagonist MRZ 2/576 produces prolonged suppression of morphine withdrawal in mice. Naunyn-Schmiedeberg's archives of pharmacology, 2000, Volume: 361, Issue:3 Topics: Analysis of Variance; Animals; Dose-Response Relationship, Drug; Male; Mice; Morphine; Naltrexone; Narcotic Antagonists; Phthalazines; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome; Tremor	2000
Opiate withdrawal in the fetal rat: a behavioral profile. Pharmacology, biochemistry, and behavior, 2000, Volume: 66, Issue:2 Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Fetus; Humans; Maternal-Fetal Exchange; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Pregnancy; Rats; Substance Withdrawal Syndrome	2000
Upregulation of galanin binding sites and GalR1 mRNA levels in the mouse locus coeruleus following chronic morphine treatments and precipitated morphine withdrawal. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2000, Volume: 23, Issue:2 Topics: Animals; Autoradiography; Behavior, Animal; Drug Administration Schedule; Female; Galanin; In Situ Hybridization; Iodine Radioisotopes; Locus Coeruleus; Mice; Mice, Inbred C57BL; Morphine; Naltrexone; Nucleus Accumbens; Receptors, Galanin; Receptors, Neuropeptide; RNA, Messenger; Substance Withdrawal Syndrome; Up-Regulation; Ventral Tegmental Area	2000
Behavioral activation induced by D(2)-like receptor stimulation during opiate withdrawal. The Journal of pharmacology and experimental therapeutics, 2000, Volume: 294, Issue:2 Topics: Analgesics, Opioid; Animals; Apomorphine; Behavior, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Synergism; Locomotion; Male; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereotyped Behavior; Substance Withdrawal Syndrome	2000
[Regulation of the central opioidergic nervous system on the emotional state of anxiety and its possible mechanisms]. Sheng li ke xue jin zhan [Progress in physiology], 1997, Volume: 28, Issue:1 Topics: Animals; Anxiety; Brain; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Rats; Serotonin; Substance Withdrawal Syndrome	1997
Expression of fos-related antigens in the nucleus accumbens during opiate withdrawal and their attenuation by a D2 dopamine receptor agonist. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2000, Volume: 23, Issue:3 Topics: Animals; Apomorphine; Behavior, Animal; Dopamine Agonists; Dopamine Antagonists; Immunohistochemistry; Lithium Chloride; Male; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Nucleus Accumbens; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Substance Withdrawal Syndrome	2000
Pharmacological validation of a new animal model of alcoholism. Journal of neural transmission (Vienna, Austria : 1996), 2000, Volume: 107, Issue:6 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Naltrexone; Narcotic Antagonists; Rats; Reproducibility of Results; Secondary Prevention; Self Administration; Substance Withdrawal Syndrome; Taurine	2000
Spinal kappa-opioid system plays an important role in suppressing morphine withdrawal syndrome in the rat. Neuroscience letters, 2000, Dec-01, Volume: 295, Issue:1-2 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Male; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, kappa; Substance Withdrawal Syndrome	2000
Plasma naltrexone during opioid detoxification. Journal of addictive diseases, 2000, Volume: 19, Issue:4 Topics: Administration, Oral; Dose-Response Relationship, Drug; Humans; Inactivation, Metabolic; Naltrexone; Narcotic Antagonists; Narcotics; Substance Withdrawal Syndrome; Time Factors	2000
The role of opioid receptors in morphine withdrawal in the infant rat. Brain research. Developmental brain research, 2000, Nov-30, Volume: 124, Issue:1-2 Topics: Animals; Animals, Newborn; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Long-Evans; Receptors, Opioid; Receptors, Opioid, mu; Somatostatin; Substance Withdrawal Syndrome	2000
Mapping of c-fos gene expression in the brain during morphine dependence and precipitated withdrawal, and phenotypic identification of the striatal neurons involved. The European journal of neuroscience, 2000, Volume: 12, Issue:12 Topics: Animals; Brain; Corpus Striatum; Drug Implants; Gene Expression Regulation; Genes, fos; Male; Morphine; Morphine Dependence; Naltrexone; Neurons; Organ Specificity; Phenotype; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substance Withdrawal Syndrome; Transcription, Genetic	2000
Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes. Drug and alcohol dependence, 2001, Jan-01, Volume: 61, Issue:2 Topics: Adrenocorticotropic Hormone; Adult; Analgesics, Opioid; Analysis of Variance; Anesthesia, General; Blood Pressure; Female; Fentanyl; Follow-Up Studies; Heart Rate; Humans; Hydrocortisone; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Respiration; Statistics, Nonparametric; Substance Withdrawal Syndrome	2001
Intraoperative high-dose remifentanil in a patient on naltrexone therapy. Anaesthesia and intensive care, 2000, Volume: 28, Issue:6 Topics: Aged; Analgesics, Opioid; Arteriovenous Fistula; Debridement; Female; Foot Ulcer; Humans; Intraoperative Complications; Naltrexone; Narcotic Antagonists; Piperidines; Remifentanil; Substance Withdrawal Syndrome	2000
Injections of an opioid antagonist into the locus coeruleus and periaqueductal gray but not the amygdala precipitates morphine withdrawal in the 7-day-old rat. Synapse (New York, N.Y.), 2001, Volume: 39, Issue:2 Topics: Age Factors; Amygdala; Animals; Animals, Newborn; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Locus Coeruleus; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Neural Pathways; Opioid-Related Disorders; Periaqueductal Gray; Quaternary Ammonium Compounds; Rats; Rats, Long-Evans; Substance Withdrawal Syndrome	2001
[Evolution and update of detoxification techniques for opiate addicts]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2000, Volume: 20, Issue:4 Topics: Animals; Buprenorphine; Humans; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome	2000
Inhibition of morphine withdrawal by the NMDA receptor antagonist MK-801 in rat is age-dependent. Synapse (New York, N.Y.), 2001, Jun-15, Volume: 40, Issue:4 Topics: Age Factors; Animals; Body Temperature; Body Weight; Central Nervous System; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Administration Routes; Excitatory Amino Acid Antagonists; Male; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Rats, Long-Evans; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome	2001
Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. Journal of neurochemistry, 2001, Volume: 77, Issue:6 Topics: Analgesics, Opioid; Animals; Benzylidene Compounds; Cell Line; Cell Membrane; Cyclic AMP; Dose-Response Relationship, Drug; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Kidney; Magnesium; Male; Mice; Mice, Inbred ICR; Morphine; Morphine Dependence; Naloxone; Naltrexone; Narcotic Antagonists; Nociceptors; Receptors, Opioid, mu; Signal Transduction; Substance Withdrawal Syndrome; Sulfur Radioisotopes; Transfection; Tritium	2001
Acute opioid withdrawal in the emergency department: inadvertent naltrexone abuse? Emergency medicine (Fremantle, W.A.), 2001, Volume: 13, Issue:3 Topics: Acute Disease; Adult; Colic; Emergency Medical Services; Female; Heroin; Heroin Dependence; Humans; Injections, Intravenous; Naltrexone; Narcotics; Substance Withdrawal Syndrome; Vomiting	2001
Cholera toxin-B subunit blocks excitatory opioid receptor-mediated hyperalgesic effects in mice, thereby unmasking potent opioid analgesia and attenuating opioid tolerance/dependence. Brain research, 2001, Nov-16, Volume: 919, Issue:1 Topics: Adjuvants, Immunologic; Administration, Oral; Analgesics, Opioid; Animals; Cells, Cultured; Cholera Toxin; Drug Administration Schedule; Drug Tolerance; Hot Temperature; Hyperalgesia; Injections, Subcutaneous; Male; Mice; Morphine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain Measurement; Receptors, Opioid; Substance Withdrawal Syndrome	2001
Unintentional rapid opioid detoxification. Emergency medicine journal : EMJ, 2001, Volume: 18, Issue:6 Topics: Adult; Female; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome	2001
Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2002, Volume: 9, Issue:1 Topics: Administration, Cutaneous; Adult; Delayed-Action Preparations; Drug Implants; Emergency Treatment; Epilepsy, Tonic-Clonic; Fatal Outcome; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pulmonary Edema; Risk Assessment; Substance Withdrawal Syndrome; Time Factors; Unconsciousness; Vomiting	2002
Outcomes of naltrexone maintenance following ultra rapid opiate detoxification versus intensive inpatient detoxification. The American journal on addictions, 2002,Winter, Volume: 11, Issue:1 Topics: Adult; Analgesics; Clonidine; Humans; Inactivation, Metabolic; Israel; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Recurrence; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome	2002
A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user. The Australian & New Zealand journal of obstetrics & gynaecology, 2002, Volume: 42, Issue:1 Topics: Adult; Dose-Response Relationship, Drug; Drug Implants; Female; Follow-Up Studies; Gestational Age; Heroin Dependence; Humans; Maternal-Fetal Exchange; Naltrexone; Narcotic Antagonists; Patient Compliance; Pregnancy; Pregnancy Outcome; Pregnancy, High-Risk; Substance Withdrawal Syndrome; Treatment Outcome	2002
Effect of precipitated morphine withdrawal on post-translational processing of prothyrotropin releasing hormone (proTRH) in the ventrolateral column of the midbrain periaqueductal gray. Journal of neurochemistry, 2002, Volume: 80, Issue:5 Topics: Animals; Blotting, Western; Brain Chemistry; Electrophoresis, Polyacrylamide Gel; Hypothalamus; Immunohistochemistry; Male; Median Eminence; Morphine; Naltrexone; Paraventricular Hypothalamic Nucleus; Peptide Fragments; Periaqueductal Gray; Proprotein Convertase 2; Protein Precursors; Protein Processing, Post-Translational; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Subtilisins; Thyrotropin-Releasing Hormone; Up-Regulation	2002
Drug treatments for alcoholism. The Harvard mental health letter, 2002, Volume: 18, Issue:10 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Substance Withdrawal Syndrome; Taurine	2002
Regional and cellular mapping of cAMP response element-mediated transcription during naltrexone-precipitated morphine withdrawal. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2002, May-01, Volume: 22, Issue:9 Topics: Amygdala; Animals; beta-Galactosidase; Corticotropin-Releasing Hormone; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Female; Genes, Reporter; Locus Coeruleus; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Morphine; Naltrexone; Nucleus Accumbens; Raphe Nuclei; Receptors, Opioid, mu; Response Elements; Substance Withdrawal Syndrome; Transcription, Genetic; Tyrosine 3-Monooxygenase; Up-Regulation; Ventral Tegmental Area	2002
Cocaine and amphetamine attenuate the discriminative stimulus effects of naltrexone in opioid-dependent rhesus monkeys. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 301, Issue:3 Topics: Amphetamine; Animals; Cocaine; Discrimination, Psychological; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Female; Macaca mulatta; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome	2002
Letter: Treatment of accidental naltrexone-induced withdrawal. The American journal of psychiatry, 1976, Volume: 133, Issue:2 Topics: Adult; Humans; Hydromorphone; Male; Methadone; Naloxone; Naltrexone; Substance Withdrawal Syndrome	1976
Naltrexone in a behavioral treatment program. NIDA research monograph, 1976, Issue:9 Topics: Behavior; Conditioning, Psychological; Extinction, Psychological; Humans; Hydromorphone; Injections; Naloxone; Naltrexone; Remission, Spontaneous; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors	1976
Clonidine hydrochloride: a nonopiate treatment for opiate withdrawal. NIDA research monograph, 1979, Volume: 27 Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	1979
Naltrexone-induced hypothermia in the rat. European journal of pharmacology, 1976, Volume: 39, Issue:2 Topics: Animals; Body Temperature Regulation; Dose-Response Relationship, Drug; Humans; Hypothermia; Morphine; Naloxone; Naltrexone; Placebos; Rats; Receptors, Opioid; Substance Withdrawal Syndrome; Substance-Related Disorders	1976
Update of naltrexone treatment. NIDA research monograph, 1978, Issue:19 Topics: Adult; Conditioning, Psychological; Female; Humans; Male; Methadone; Naloxone; Naltrexone; Narcotics; Receptors, Opioid; Social Adjustment; Substance Withdrawal Syndrome; Substance-Related Disorders	1978
Naltrexone in the treatment of opiate dependence. NIDA research monograph, 1978, Issue:19 Topics: Adolescent; Adult; Follow-Up Studies; Forecasting; Heroin Dependence; Humans; Male; Methadone; Naloxone; Naltrexone; Narcotics; New York City; Psychotherapy; Receptors, Opioid; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders	1978
Conditioning effects of narcotics in humans. NIDA research monograph, 1978, Issue:18 Topics: Conditioning, Psychological; Cyclazocine; Drug Tolerance; Humans; Naltrexone; Narcotics; Substance Withdrawal Syndrome	1978
Withdrawal from endogenous opiates. The American journal of psychiatry, 1979, Volume: 136, Issue:3 Topics: Endorphins; Humans; Naloxone; Naltrexone; Schizophrenia; Substance Withdrawal Syndrome	1979
Stability of Met-enkephalin content in brain structures of morphine-dependent or foot shock-stressed rats. Nature, 1977, Aug-04, Volume: 268, Issue:5619 Topics: Animals; Brain; Corpus Striatum; Enkephalins; Humans; Hypothalamus; Male; Morphine Dependence; Naltrexone; Oligopeptides; Rats; Stress, Psychological; Substance Withdrawal Syndrome	1977
The pharmacology of thebaine in the chronic spinal dog. Drug and alcohol dependence, 1978, Volume: 3, Issue:2 Topics: Animals; Dogs; Humans; Naloxone; Naltrexone; Spinal Cord; Substance Withdrawal Syndrome; Substance-Related Disorders; Thebaine; Time Factors	1978
Discriminative stimulus effects of naltrexone in the morphine-dependent rat. The Journal of pharmacology and experimental therapeutics, 1979, Volume: 211, Issue:3 Topics: Animals; Generalization, Stimulus; Humans; Male; Morphine; Morphine Dependence; Naloxone; Naltrexone; Narcotic Antagonists; Prejudice; Rats; Substance Withdrawal Syndrome; Time Factors	1979
Possible withdrawal from endogeneous opiates in schizophrenics. The American journal of psychiatry, 1978, Volume: 135, Issue:3 Topics: Female; Humans; Male; Naloxone; Naltrexone; Schizophrenia; Substance Withdrawal Syndrome; Time Factors	1978
[Precipitation and prevention of abstinence in acutely morphinized rats and mice: comparisons between naloxone, naltrexone, and diprenorphine (author's transl)]. Psychopharmacology, 1976, Aug-26, Volume: 49, Issue:1 Topics: Animals; Diprenorphine; Humans; Male; Mice; Morphinans; Morphine; Morphine Dependence; Naloxone; Naltrexone; Rats; Substance Withdrawal Syndrome; Time Factors	1976
Naloxone-precipitated withdrawal: a method for rapid induction onto naltrexone. Clinical pharmacology and therapeutics, 1977, Volume: 21, Issue:4 Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Heroin Dependence; Humans; Male; Methadone; Methods; Naloxone; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders	1977
Comparison of withdrawal precipitating properties of various morphine antagonists and partial agonists in relation to their stereospecific binding to brain homogenates. Psychopharmacologia, 1976, Volume: 46, Issue:1 Topics: Benzomorphans; Binding Sites; Brain; Humans; Levallorphan; Morphine Dependence; Nalorphine; Naloxone; Naltrexone; Narcotic Antagonists; Pentazocine; Receptors, Drug; Sodium; Stereoisomerism; Subcellular Fractions; Substance Withdrawal Syndrome	1976
Reinstatement of precipitated narcotic withdrawal hypothermia in the rat. Life sciences, 1976, Jun-01, Volume: 18, Issue:11 Topics: Animals; Body Temperature; Female; Humans; Morphine; Naloxone; Naltrexone; Rats; Substance Withdrawal Syndrome; Substance-Related Disorders	1976
The theoretical basis of narcotic addiction treatment with narcotic antagonists. NIDA research monograph, 1976, Issue:9 Topics: Animals; Conditioning, Psychological; Drug Administration Schedule; Extinction, Psychological; Humans; Naltrexone; Narcotic Antagonists; Rats; Satiation; Self Medication; Substance Withdrawal Syndrome; Substance-Related Disorders	1976
Interactions of narcotics, narcotic antagonists, and ethanol during acute, chronic, and withdrawal states. Annals of the New York Academy of Sciences, 1976, Volume: 281 Topics: Alcohol Drinking; Animals; Animals, Newborn; Dextrorphan; Drug Interactions; Ethanol; Humans; Levorphanol; Male; Methadone; Methadyl Acetate; Mice; Mice, Inbred C57BL; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors	1976
Activation of the zinc finger encoding gene krox-20 in adult rat brain: comparison with zif268. Brain research. Molecular brain research, 1992, Volume: 13, Issue:3 Topics: Animals; Apomorphine; Benzazepines; Brain; DNA-Binding Proteins; Early Growth Response Protein 1; Early Growth Response Protein 2; Electroshock; Haloperidol; Immediate-Early Proteins; Male; Morphine; Naltrexone; Nucleic Acid Hybridization; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Reserpine; Seizures; Substance Withdrawal Syndrome; Transcription Factors; Transcription, Genetic; Zinc Fingers	1992
Effects of beta-funaltrexamine on butorphanol dependence. Pharmacology, biochemistry, and behavior, 1992, Volume: 42, Issue:1 Topics: Animals; Behavior, Animal; Body Temperature; Body Weight; Butorphanol; Dose-Response Relationship, Drug; Injections, Intraventricular; Male; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Reinforcement Schedule; Substance Withdrawal Syndrome; Substance-Related Disorders	1992
Induction of the c-fos proto-oncogene during opiate withdrawal in the locus coeruleus and other regions of rat brain. Brain research, 1990, Aug-20, Volume: 525, Issue:2 Topics: Animals; Blotting, Northern; Brain; DNA-Binding Proteins; Locus Coeruleus; Male; Morphine; Naltrexone; Organ Specificity; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Proto-Oncogenes; Rats; Rats, Inbred Strains; RNA; RNA, Messenger; Substance Withdrawal Syndrome; Transcription Factors	1990
Excitatory amino acids and morphine withdrawal: differential effects of central and peripheral kynurenic acid administration. Psychopharmacology, 1991, Volume: 105, Issue:4 Topics: Amino Acids; Analysis of Variance; Animals; Behavior, Animal; Injections, Intraventricular; Kynurenic Acid; Locus Coeruleus; Male; Morphine Dependence; Naltrexone; Neurons; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome	1991
Experience with clonidine-naltrexone for rapid opiate detoxification. Journal of substance abuse treatment, 1991, Volume: 8, Issue:4 Topics: Adult; Clonidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Male; Middle Aged; Naltrexone; Neurologic Examination; Substance Withdrawal Syndrome	1991
NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. European journal of pharmacology, 1991, May-02, Volume: 197, Issue:1 Topics: Animals; Behavior, Animal; Dizocilpine Maleate; Electrophysiology; Isoquinolines; Locus Coeruleus; Male; Morphine; Naltrexone; Norepinephrine; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome	1991
Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys. Psychopharmacology, 1991, Volume: 104, Issue:3 Topics: Alcohol Drinking; Animals; Choice Behavior; Dose-Response Relationship, Drug; Drinking Behavior; Macaca mulatta; Male; Naltrexone; Substance Withdrawal Syndrome	1991
Rapid transition from methadone maintenance to naltrexone. Lancet (London, England), 1990, Jan-13, Volume: 335, Issue:8681 Topics: Flumazenil; Humans; Methadone; Midazolam; Naltrexone; Substance Withdrawal Syndrome	1990
Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. The American journal of psychiatry, 1991, Volume: 148, Issue:7 Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methadone; Midazolam; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	1991
Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. The Journal of neuroscience : the official journal of the Society for Neuroscience, 1990, Volume: 10, Issue:7 Topics: Adenylyl Cyclases; Animals; Behavior, Animal; GTP-Binding Proteins; Locus Coeruleus; Male; Morphine Dependence; Naltrexone; Neurons; Protein Kinases; Rats; Rats, Inbred Strains; Reference Values; Substance Withdrawal Syndrome	1990
Physical dependence on morphine using the mu receptor deficient CXBK mouse. Progress in clinical and biological research, 1990, Volume: 328 Topics: Animals; Mice; Mice, Inbred C57BL; Morphine Dependence; Naloxone; Naltrexone; Receptors, Opioid; Receptors, Opioid, mu; Species Specificity; Substance Withdrawal Syndrome	1990
"Paradoxical" analgesia and aggravated morphine dependence induced by opioid antagonists. Life sciences, 1990, Volume: 47, Issue:6 Topics: Animals; Body Weight; Indoles; Male; Morphinans; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Pain Measurement; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome; Substance-Related Disorders	1990
Context-specific morphine withdrawal in rats: duration and effects of clonidine. Behavioral neuroscience, 1990, Volume: 104, Issue:5 Topics: Animals; Arousal; Association Learning; Clonidine; Male; Morphine; Morphine Dependence; Motor Activity; Naltrexone; Rats; Social Environment; Substance Withdrawal Syndrome; Weight Loss	1990
Tolerance and dependence after continuous morphine infusion from osmotic pumps measured by operant responding in rats. Psychopharmacology, 1990, Volume: 100, Issue:4 Topics: Analgesics; Animals; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Tolerance; Food; Infusion Pumps; Male; Morphine Dependence; Naltrexone; Rats; Rats, Inbred Strains; Reaction Time; Reinforcement Schedule; Substance Withdrawal Syndrome	1990
Phosphodiesterase inhibitors potentiate opiate-antagonist discrimination by morphine-dependent rats. Pharmacology, biochemistry, and behavior, 1989, Volume: 33, Issue:4 Topics: 1-Methyl-3-isobutylxanthine; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Body Weight; Discrimination, Psychological; Dose-Response Relationship, Drug; Drug Synergism; Male; Morphine; Naltrexone; Narcotic Antagonists; Papaverine; Phosphodiesterase Inhibitors; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome; Substance-Related Disorders	1989
Evidence of single dose opioid dependence in 12- to 14-day-old chicken embryos. Pharmacology, biochemistry, and behavior, 1989, Volume: 34, Issue:4 Topics: 1-Methyl-3-isobutylxanthine; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Chick Embryo; Methadone; Morphine Dependence; Motor Activity; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pyrrolidines; Receptors, Opioid; Substance Withdrawal Syndrome	1989
Down-regulation of proopiomelanocortin synthesis and beta-endorphin utilization in hypothalamus of morphine-tolerant rats. Journal of molecular neuroscience : MN, 1989, Volume: 1, Issue:1 Topics: Animals; beta-Endorphin; Corpus Striatum; Drug Tolerance; Enkephalin, Methionine; Enkephalins; Hypothalamus; Male; Morphine; Naltrexone; Pro-Opiomelanocortin; Protein Precursors; Rats; Rats, Inbred Strains; Reference Values; RNA, Messenger; Substance Withdrawal Syndrome	1989
Procedures that produce context-specific tolerance to morphine in rats also produce context-specific withdrawal. Behavioral neuroscience, 1989, Volume: 103, Issue:4 Topics: Animals; Brain; Dose-Response Relationship, Drug; Drug Tolerance; Male; Morphine; Morphine Dependence; Naltrexone; Nociceptors; Rats; Rats, Inbred Strains; Receptors, Opioid; Social Environment; Substance Withdrawal Syndrome; Thermosensing	1989
Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. The Journal of pharmacology and experimental therapeutics, 1989, Volume: 250, Issue:3 Topics: Animals; Discrimination Learning; Dose-Response Relationship, Drug; Female; Macaca mulatta; Morphine; Naltrexone; Receptors, Opioid; Substance Withdrawal Syndrome	1989
Effects of a selective kappa-opioid agonist, U-50,488H, on morphine dependence in rats. European journal of pharmacology, 1989, Oct-24, Volume: 170, Issue:1-2 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Behavior, Animal; Male; Morphine Dependence; Naltrexone; Pyrrolidines; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, kappa; Substance Withdrawal Syndrome	1989
Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: attenuation by lesions of the nucleus paragigantocellularis. Brain research, 1989, Dec-29, Volume: 505, Issue:2 Topics: Action Potentials; Animals; Kynurenic Acid; Locus Coeruleus; Male; Medulla Oblongata; Morphine; Naltrexone; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome	1989
Naltrexone and clonidine in heroin withdrawal treatment. The British journal of psychiatry : the journal of mental science, 1989, Volume: 154 Topics: Clonidine; Heroin; Humans; Naltrexone; Substance Withdrawal Syndrome	1989
Does the blockade of opioid receptors influence the development of ethanol dependence? Alcohol and alcoholism (Oxford, Oxfordshire), 1987, Volume: 22, Issue:2 Topics: Alcoholism; Animals; Diprenorphine; Female; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Receptors, Opioid; Seizures; Substance Withdrawal Syndrome	1987
Endogenous opioids in cerebrospinal fluid of opioid-dependent humans. Biological psychiatry, 1988, Volume: 24, Issue:6 Topics: Adult; beta-Endorphin; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Radioimmunoassay; Radioligand Assay; Receptors, Opioid; Substance Withdrawal Syndrome	1988
Blood pressure monitoring at home for rapid opioid withdrawal with clonidine and naltrexone. Lancet (London, England), 1987, Mar-14, Volume: 1, Issue:8533 Topics: Administration, Oral; Adult; Blood Pressure Determination; Clonidine; Drug Therapy, Combination; Female; Heroin; Home Nursing; Humans; Monitoring, Physiologic; Naltrexone; Substance Withdrawal Syndrome; Telephone	1987
A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life sciences, 1986, Jul-07, Volume: 39, Issue:1 Topics: Adolescent; Adult; beta-Endorphin; Circadian Rhythm; Endorphins; Heroin Dependence; Humans; Hydrocortisone; Naltrexone; Substance Withdrawal Syndrome	1986
Naltrexone. Journal of substance abuse treatment, 1985, Volume: 2, Issue:2 Topics: Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain; Pituitary Gland; Receptors, Opioid; Substance Withdrawal Syndrome	1985
An analysis of naltrexone precipitated abstinence in morphine-dependent chronic spinal dogs. The Journal of pharmacology and experimental therapeutics, 1987, Volume: 240, Issue:2 Topics: Animals; Behavior, Animal; Cordotomy; Dogs; Dose-Response Relationship, Drug; Female; Morphine Dependence; Naloxone; Naltrexone; Receptors, Opioid; Substance Withdrawal Syndrome	1987
Opiate withdrawal: inpatient versus outpatient programmes. British medical journal (Clinical research ed.), 1986, Aug-09, Volume: 293, Issue:6543 Topics: Clonidine; Heroin; Hospitalization; Humans; Naltrexone; Substance Withdrawal Syndrome	1986
Opioid withdrawal and naltrexone induction in 48-72 hours with minimal drop-out, using a modification of the naltrexone-clonidine technique. The British journal of psychiatry : the journal of mental science, 1988, Volume: 153 Topics: Adolescent; Adult; Clonidine; Diazepam; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotics; Substance Withdrawal Syndrome; Time Factors	1988
Effect of chronic naltrexone administration and its withdrawal on the regional activity of neurons that contain norepinephrine, dopamine and serotonin. Brain research, 1988, Mar-01, Volume: 442, Issue:2 Topics: Animals; Brain; Dopamine; Female; Naltrexone; Neurons; Norepinephrine; Organ Specificity; Rats; Rats, Inbred Strains; Serotonin; Substance Withdrawal Syndrome	1988
Is the motivational effect of opiate withdrawal reflected by common somatic indices of precipitated withdrawal? A place conditioning study in the rat. Brain research, 1987, Aug-25, Volume: 418, Issue:2 Topics: Animals; Avoidance Learning; Behavior, Animal; Body Weight; Dose-Response Relationship, Drug; Drug Implants; Male; Morphine; Motivation; Naltrexone; Quaternary Ammonium Compounds; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome	1987
Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. The American journal of drug and alcohol abuse, 1987, Volume: 13, Issue:1-2 Topics: Adult; Ambulatory Care; Clonidine; Drug Therapy, Combination; Female; Heroin; Humans; Male; Naltrexone; Substance Withdrawal Syndrome	1987
The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. The American journal of psychiatry, 1986, Volume: 143, Issue:7 Topics: Adult; Blood Pressure; Clonidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Rate; Humans; Male; Methadone; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders	1986
Effects of beta-funaltrexamine (beta-FNA) on morphine dependence in rats and monkeys. European journal of pharmacology, 1986, Apr-29, Volume: 123, Issue:3 Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Macaca mulatta; Male; Morphine Dependence; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Species Specificity; Substance Withdrawal Syndrome; Time Factors	1986
Effect of morphine treatment and withdrawal on endogenous methionine- and leucine-enkephalin levels in primate brain. Biochemical pharmacology, 1986, Oct-01, Volume: 35, Issue:19 Topics: Animals; Brain Chemistry; Chlorocebus aethiops; Enkephalin, Leucine; Enkephalin, Methionine; Female; Male; Morphine; Naltrexone; Substance Withdrawal Syndrome	1986
[Naloxone and naltrexone antagonism of various central effects of morphine]. Bollettino della Societa italiana di biologia sperimentale, 1986, Oct-30, Volume: 62, Issue:10 Topics: Animals; Behavior, Animal; Central Nervous System; Female; Male; Mice; Morphine; Naloxone; Naltrexone; Pain Measurement; Rats; Substance Withdrawal Syndrome	1986
[Activity of naloxone and naltrexone on the development of the morphine withdrawal syndrome]. Bollettino della Societa italiana di biologia sperimentale, 1986, Oct-30, Volume: 62, Issue:10 Topics: Animals; Behavior, Animal; Female; Male; Mice; Morphine Dependence; Naloxone; Naltrexone; Rats; Substance Withdrawal Syndrome	1986
REM sleep deprivation decreases the grooming and shaking behaviour induced by enkephalinase inhibitor or opiate withdrawal. Pharmacology, biochemistry, and behavior, 1985, Volume: 23, Issue:3 Topics: Animals; Anti-Bacterial Agents; Glycopeptides; Grooming; Injections, Intraventricular; Male; Naltrexone; Narcotics; Neprilysin; Protease Inhibitors; Rats; Rats, Inbred Strains; Sleep Deprivation; Sleep, REM; Substance Withdrawal Syndrome; Substance-Related Disorders	1985
Discriminative stimulus effects of morphine withdrawal in the dependent rat: suppression by opiate and nonopiate drugs. The Journal of pharmacology and experimental therapeutics, 1985, Volume: 233, Issue:1 Topics: Animals; Body Weight; Clonidine; Haloperidol; Humans; Male; Morphine Dependence; Naloxone; Naltrexone; Narcotics; Rats; Rats, Inbred Strains; Stereoisomerism; Substance Withdrawal Syndrome	1985
Effects of beta-funaltrexamine in normal and morphine-dependent rhesus monkeys: observational studies. The Journal of pharmacology and experimental therapeutics, 1985, Volume: 235, Issue:2 Topics: Animals; Azocines; Behavior, Animal; Dose-Response Relationship, Drug; Injections, Intraventricular; Injections, Subcutaneous; Macaca mulatta; Morphine; Muscle Relaxation; Naloxone; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors	1985
Clinical use of naltrexone (EN-1639A): Part I: Safety and efficacy in pilot studies. The American journal of drug and alcohol abuse, 1974, Volume: 1, Issue:2 Topics: Adult; Ambulatory Care; Drug Evaluation; Female; Heroin Dependence; Humans; Legislation, Drug; Male; Middle Aged; Naloxone; Naltrexone; Nausea; New York City; Pilot Projects; Sleep Initiation and Maintenance Disorders; Substance Withdrawal Syndrome; United States	1974